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Infertilidade masculina, disfunção espermatogénica, variantes raras de número de 
cópia, deleções de uma única cópia, haploinsuficiência, biomarcadores genéticos, 
gene WT1  
 
 
A azoospermia afeta aproximadamente 15% de todos os homens inférteis e é 
frequentemente causada por anomalias cromossómicas e microdeleções do 
cromossoma Y. No entanto, em aproximadamente 70% dos casos de 
azoospermia não-obstrutiva (NOA) as causas permanecem por identificar. Nos 
últimos anos, a descoberta de variantes genómicas de número de cópia (CNVs), 
como as causadas por deleções, revelou uma fonte de variação genómica que 
afecta a dosagem génica e que poderá resultar em haploinsuficiência. De facto, 
observa-se uma sobre-representação de CNVs raros (<1% na população), 
sobretudo de grandes deleções de novo, em pacientes com diferentes distúrbios 
do desenvolvimento, comparados com controlos saudáveis. Porém, uma possível 
contribuição, para a infertilidade masculina, de variantes estruturais ligados ao 
cromossoma X e aos autossomas foi ainda pouco explorada. 
Este estudo foca-se na validação de deleções encontradas apenas em pacientes 
inférteis, no cromossoma X e em 11p13, que contêm genes candidatos a 
participar na espermatogénese. Estas deleções, previamente identificadas por 
arrays de oligonucleótidos, de elevada densidade (Affymetrix 6.0 SNP Array), 
numa coorte de 171 pacientes Portugueses com disfunção severa da 
espermatogénese (NOA e oligozoospermia severa), foram agora confirmadas por 
técnicas convencionais de genética molecular. Adicionalmente, a caraterização 
dos locais de quebra nestas deleções foi realizada por aCGH. Ainda que não se 
tenham validado as deleções menos extensas (em Xq21.1, Xq25, Xp11.4, Xq22.1 
e Xq26.3), confirmou-se a nulizigotia em Xq28 nestes indivíduos, que abrange 
genes candidatos com uma função sugestiva na espermatogénese: MAGE-A8, 
expresso em testículo e em alguns cancros e o microRNA hsa-miR-4330, 
envolvido na regulação pós-transcricional de vários genes com expressão na linha 
germinal. Foi ainda validada, por MLPA, uma deleção extensa num paciente 
infértil não-sindrómico da nossa coorte. Estes resultados apontam a 
haploinsuficiência de WT1 como a causa mais provável de azoospermia neste 
paciente, já que não foram detetadas mutações germinais no alelo restante. 
Mutações no gene WT1, que codifica um factor de transcrição muito conservado, 
crucial para o desenvolvimento e manutenção gonadal em mamíferos, geralmente 
interferem com a ligação desta proteína ao DNA e estão principalmente 
associadas a síndromes que envolvem anomalias reprodutivas. Motivados pela 
nossa descoberta de uma deleção de WT1 num homem infértil embora saudável, 
decidimos abordar a contribuição de mutações exónicas no gene WT1 para a 
azoospermia isolada. Testámos a hipótese de que mutações localizadas em 
domínios que não aqueles essenciais à ligação ao DNA pudessem resultar na 
disfunção não-sindrómica da espermatogénese. Assim, analisámos a sequência 
codificante de WT1 num subgrupo de 40 pacientes azoospérmicos. Como 
resultado, descrevemos uma nova variação missense c.185C>T (P130L; 
ENST00000332351) no primeiro exão de WT1, inserida no domínio proteico de 
auto-associação. A nova variante descrita deverá ter um impacto menos drástico 
na função da proteína WT1, comparativamente com as mutações descritas no 
mesmo exão até à data, as quais resultam em proteínas truncadas e fenótipos 
severos de disfunção gonadal, incluindo a formação de tumores renais. Estes 
resultados revelam novos genes candidatos a um papel na espermatogénese e 
sugerem que a haploinsuficiência de proteínas importantes para o 
desenvolvimento do sistema reprodutor masculino podem resultar em 
azoospermia. Estudos futuros poderão clarificar a utilidade dos nossos genes 
candidatos como biomarcadores da infertilidade masculina. A implementação de 
novos biomarcadores beneficiaria os doentes azoospérmicos através da melhoria 
do diagnóstico, aconselhamento genético e acompanhamento destes pacientes, 
podendo vir a limitar a necessidade de procedimentos invasivos. 
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Azoospermia affects approximately 15% of all infertile males and it is frequently 
caused by chromosomal abnormalities and Yq microdeletions. However, despite 
considerable research efforts in the last decades, in approximately 70% of the 
cases of non-obstructive azoospermia (NOA) the causes are yet to be identified.  
In the last years, the discovery of genomic copy number variants, such as those 
caused by deletions, revealed a source of genomic variation which impacts gene 
dosage and may result in haploinsufficiency. In fact, rare CNVs (<1% population), 
mainly large de novo deletions, are over-represented in patients with different 
developmental disorders, compared to healthy controls. However, a possible 
contribution of X-linked and autosomal structural variants to male infertility is still 
largely unexplored.  
This study focused on the validation of rare patient-specific deletions found on the 
X chromosome and at 11p13 of infertile patients, which harbor candidate 
spermatogenesis genes. These deletions had been previously identified by high 
density oligonucleotide arrays (Affymetrix 6.0 SNP Array), in a cohort of 171 
Portuguese patients with severe spermatogenic impairment (non-obstructive 
azoospermia and severe oligozoospermia) and were now confirmed by 
conventional molecular genetics techniques. Additionally, breakpoint 
characterization was carried out by aCGH. In fact, even though the smaller 
deletions (at Xq21.1, Xq25, Xp11.4, Xq22.1 and Xq26.3) were not validated, we 
confirmed nullizygosity at Xq28 in two patients, spanning either MAGE-A8, a 
known cancer-testis antigen, or hsa-miR-4330, a microRNA involved in post-
transcription regulation, both with a suggestive role in spermatogenesis pathways.  
We have also validated by MLPA a large deletion at 11p13, in a non-syndromic 
infertile patient from our cohort. These results support WT1 haploinsufficiency as 
the likely cause of azoospermia in this patient, as no other germline mutations were 
detected in the remaining WT1 copy.  
Mutations in WT1, an evolutionarily conserved transcription factor crucial for 
gonadal development and maintenance in mammals, typically interfere with the 
DNA-binding properties of the protein and are mainly associated with syndromes 
involving reproductive abnormalities. Motivated by our finding of a WT1 deletion in 
an infertile but otherwise healthy man we addressed the contribution of WT1 exonic 
mutations to isolated azoospermia. We reasoned that mutations located in domains 
not essential for DNA binding could result in non-syndromic spermatogenic 
impairment. Thus, we analyzed the WT1 coding sequence in a subgroup of 40 
azoospermic patients. As a result of the exon screening, we report a novel 
c.185C>T (P130L; ENST00000332351) WT1 missense variant on exon 1, within 
the protein self-association domain. While all exon 1 mutations as yet reported 
result in truncated proteins and severe phenotypes, including the formation of renal 
tumors, this novel variant is expected to have a milder impact on WT1 function. 
These results reveal new candidate genes for a role in spermatogenesis and 
suggest that haploinsufficiency of proteins important for the development of the 
male reproductive system can lead to azoospermia. Further studies will clarify the 
utility of our candidate genes as biomarkers of male infertility. The implementation 
of new biomarkers would benefit azoospermic men by improving diagnosis, genetic 
counseling and patient care, eventually limiting the need for invasive procedures.   
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Abbreviations 
aCGH  Array Comparative Genomic hybridization 
AZF  Azoospermia Factor Region  
bp   Base Pair 
CNV  Copy Number Variant 
CT   Cancer-Testis 
ddNTP  Dideoxyribonucleotide triphosphate 
DDS  Denys-Drash Syndrome 
dNTP  Deoxyribonucleotide triphosphate 
FSH  Follicle-Stimulating Hormone 
HR   Homologous Recombination 
kb   Thousand base pairs 
LH   Luteinizing Hormone 
MLPA  Multiplex Ligation-dependent Probe Amplification 
MSCI  Meiotic Sex Chromosome Inactivation 
NAHR  Non-Allelic Homologous Recombination 
NOA  Non-Obstructive Azoospermia 
OA   Obstructive Azoospermia   
PAR  Pseudo-Autosomal Region 
PCR  Polymerase Chain Reaction 
SCOS  Sertoli Cell-Only Syndrome 
SNP  Single Nucleotide Polymorphism 
WAGR  Wilms’ tumor, Aniridia, Genitourinary abnormalities, Retardation  
WHO  World Health Organization 
WT1  Wilms’ Tumor 1 gene 
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Introduction 
 
1. Genomic Variation 
Variation between genomes of different individuals is a key biological determinant 
underpinning evolution and defining the heritable basis of phenotypes [9]. Before the arrival 
of DNA sequencing technology, the first differences observed in our genetic content were 
mainly changes in the number and structure of chromosomes, such as aneuploidies, 
rearrangements and fragile sites. These were large enough to be identified using a 
microscope and thus termed microscopic structural variants. Later on, with the appearance 
of molecular biology and DNA sequencing, smaller and more abundant alterations could be 
observed. These modifications include single nucleotide polymorphisms (SNPs), various 
repetitive elements involving short DNA sequences (such as micro- and minisatellites) and 
small insertions, deletions and duplications (usually <1 kb), termed sub-microscopic 
structural variants [4]. 
From the several sources of variation listed, only deletions, duplications and insertions 
are responsible for changes in copy number [4]. Copy number variants (CNVs) were originally 
defined as events greater than 1 kb in size, yet with the sequencing of human genomes now 
becoming routine, the operational spectrum of CNVs has widened to include much smaller 
events such as those >50 bp in length [10]. Furthermore, CNVs have been thoroughly 
characterized in the human genome leading to the prediction that these variants are as 
important as SNPs in their contribution to genomic variation. In fact, 12% of the human 
genome is variable in copy number [11], which implies the presence of variable numbers of 
copies of large, multi-kilobase genomic regions, with a predominance of smaller size 
rearrangements (<20 kb) [12,13]. This diversity is likely to be responsible for a significant 
proportion of normal phenotypic variation. Indeed, the genomic regions encompassed by 
CNVs usually contain hundreds of genes and other functional elements, such as regulatory 
sequences [10,14].  
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CNV and Disease  
Generally CNVs are assigned to one of two main categories. The first category includes 
common variants or copy number polymorphisms (CNP), occurring with an overall frequency 
of greater than 1%. The second class of CNVs includes rare variants which occur in less than 
1% of the population. Over-representation of rare structural variants in patients compared to 
healthy controls has been observed in several illnesses such as mental disorders, obesity and 
Alzheimer’s disease [15,16,17]. Additionally, large association studies are underway by the 
Wellcome Trust Case Control Consortium that is investigating genomic structural variation in 
common diseases such as type 1 and type 2 diabetes, rheumatoid arthritis, Crohn’s disease, 
schizophrenia and Parkinson’s disease (http://www.wtccc.org.uk/). The rationale underlying 
these studies is that common CNVs, as well as a collection of rare structural variants of recent 
origin, may provide the genetic basis of variation in disease susceptibility [12,13,18]. In fact, due 
to a recent explosive growth human populations have accumulated an excess of rare variants 
that may predispose to disease [19]. 
CNVs may trigger or predispose to disease by impacting gene dosage, either alone or in 
combination with other genetic or environmental factors. For instance, single-copy deletions 
of dosage-sensitive genes may lead to imbalance of gene expression termed 
haploinsufficiency, and consequently lead to decreased protein production and physiological 
response. Likewise, a deletion may unmask a recessive deleterious allele present on the 
remaining gene copy (in the case of autosomes), resulting in the exclusive production of 
mutant proteins which may exhibit negative impact on physiological function (Fig. 1). 
Additionally, alterations in regulatory elements by deletion or duplication could also alter 
gene expression [4]. 
Fig. 1 – Consequences of single copy 
deletions. Blue – normal allele. Red – 
Deleterious recessive allele. (Adapted 
from Feuk 2006 [4])  
Deleterious allele 
unmasked 
Haploinsufficiency 
Dosage imbalance 
Autosomes 
 Rare Structural Variants in Severe Spermatogenic Impairment 
 
Catarina Morais Seabra  Page  7 
 
Mechanisms of CNV Formation  
Changes in chromosome structure leading to copy number variation can occur through 
two general mechanisms: 
 Homologous recombination  
 Non-homologous  recombination  
Homologous recombination occurs when sequences are exchanged between two identical 
strands of DNA and, thus, there will be no modification if the damaged DNA strand is repaired 
by using its homologous sequence either from the sister chromatid or the homologous 
chromosome. However, during the repair process, the presence of identical sequences from a 
different chromosomal position may activate a crossover event where it normally would not 
occur. As a result of this aberrant recombination event, known as non-allelic homologous 
recombination (NAHR), deletion/duplication of a certain genomic region occurs. Indeed, all 
mechanisms that repair a damaged molecule using sequence from a non-homologous 
template can potentially change the structure of chromosomes [20,21]. 
CNVs are not randomly distributed throughout the genome and tend to be clustered in 
regions of complex genomic architecture, rich in direct and inverted low copy repeats [21]. 
Moreover, Conrad et al. (2010) [22] verified that the mutational mechanisms generating CNVs 
differ depending on the size of the genomic alteration. NAHR has a predominant role in larger 
CNV formation, whereas intra- and inter-allelic exchanges at variable number tandem repeats 
and dispersed duplications are more commonly observed with smaller CNVs [22].  
Regarding the breakpoint signatures of deletions and duplications, duplications have 
been reported to be more likely to be formed by NAHR, variable number tandem repeats and 
retrotransposition, and are more enriched for breakpoint-associated sequence motifs than 
deletions. Thus, the formation of duplications is more likely to be sequence-dependent than 
deletions [22]. 
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CNV Measurement 
During the past years, there has been an exponential growth in the knowledge of the 
structure and function of the human genome, in large part due to the completion of the 
Human Genome Project, as well as the creation of tools that allow the interrogation of the 
entire genome in a single study [23]. In fact, several methods have been developed for 
measurement of copy number variation, which can either be locus specific or genome-wide 
(Table 1). These are mostly array based or polymerase chain reaction (PCR) based, giving 
different degrees of resolution, precision and throughput [14]. Array-based genome-wide CNV 
analysis, by array comparative genomic hybridization (aCGH) or SNP array, allows the query 
of tens or hundreds of thousands of regions across the genome, in order to identify common 
and rare CNVs associated with a particular phenotype [23]. On the other hand, PCR-based 
experimental approaches are the most robust assays for screening targeted regions of the 
genome. Quantitative PCR (qPCR) works well for scoring individual deletions and 
duplications, whereas alternative PCR-based methods for the simultaneous interrogation of 
multiple regions, such as MLPA, can score up to 40 regions in one experiment [4]. 
 
Table 1 - Strengths and limitations of the different methods for CNV detection. 
Methods Strengths Limitations 
G
e
n
o
m
e
-w
id
e
 S
c
a
n
s 
SNP Array 
 Provides genotyping information 
 Can serve a dual role for SNP and 
CNV-based association studies 
 Probe design is specific to single-
nucleotide differences 
 Limited power to detect CNV 
<20 kb 
 Per probe, SNP microarrays 
tend to offer lower signal-to-
noise ratio than do the best 
array CGH platforms. 
Array CGH 
(Oligonucleotide-
based) 
 Complete genome coverage  
 Accurate definition of CNV 
boundaries 
 Availability of custom, high-probe-
density arrays 
 Hybridization intensities have a 
poor signal-to-noise ratio that 
can lead to considerable 
experimental variability between 
studies 
Ta
rg
e
te
d
 
S
c
a
n
 
MLPA 
 Alternative targeted PCR-based 
approach for simultaneous 
analysis of multiple genomic 
regions 
 Employed for loci-specific 
studies  
 Restricted throughput and 
scale 
 
 
The greatest challenge in CNV analysis is to predict the functional impact of novel or rare 
variants. In these cases precisely mapping the CNV breakpoint is an essential task, not only to 
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assess the functional content of the variant, but also to identify signatures of the underlying 
mutational mechanisms [22]. In fact, a change in copy number requires a change in 
chromosome structure, joining two formerly separated DNA sequences and these junctions 
might give important insights into how the structural change was formed and through 
familial analysis it allows to determine if the rearrangement arose de novo [21]. 
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2. Spermatogenesis Overview  
Spermatogenesis is the process responsible for the transformation of male germ cells into 
mature gametes (the spermatozoa) throughout life, beginning at puberty [3,24]. This occurs in 
the testes, where male gametes are produced and transported through a series of ducts in 
preparation for fertilization [3]. For successful gamete formation there must be a correct 
interplay of endocrine factors within the hypothalamic-pituitary-gonadal axis and of 
autocrine, paracrine and juxtacrine interactions between the spermatogenic germ cells 
within the seminiferous tubules and the somatic cells that reside inside (Sertoli cells), 
between (Leydig and other interstitial cells) and within the wall of the tubules, as well as 
secretory factors of the epididymis (Fig. 2) [24]. Moreover, spermatogenesis is a highly 
orchestrated process which involves the renewal and differentiation of spermatogonial stem 
cells into rapidly proliferating spermatogonia, spermatocytes and spermatids, before the 
release of a spermatozoon into the tubule lumen, through three strictly regulated processes 
[3,24,25]:  
 Mitosis (cell proliferation)  
 Meiosis (production of  haploid cells)  
 Spermiogenesis (cell differentiation) 
There is a synchronized development of spermatozoa within the seminiferous tubules in 
successive cycles and each stage is morphologically distinct [3]. Initially, pluripotent 
spermatogonia undergo several rounds of mitosis before differentiating into pre-leptotene 
primary spermatocytes which mark entry into meiosis I. Primary spermatocytes spend 
several weeks in meiosis I prophase where chromosomes condense (leptotene) and pair up 
(zygotene) and the synaptonemal complex assembles along homologous chromosomes 
where recombination takes place (pachytene) [25]. Subsequently, the synaptonemal complex 
disassembles (diplotene) and DNA further condenses (diakinesis) before the first meiotic 
division (metaphase I). The progression of prophase I is regulated by many factors including 
those involved in DNA repair, homologous recombination as well as structural proteins [25].  
During metaphase I, spermatocytes move towards the tubule lumen and after diakinesis 
secondary spermatocytes rapidly go through meiosis II and become round spermatids. These 
cells undergo a final phase of differentiation - spermiogenesis – and become spermatozoa. 
Therefore, defects that may occur in any of these three vital steps may compromise male 
fertility [24,25].  
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Primordial Germ Cell 
Spermatogonia 
Primary 
Spermatocyte 
Secondary 
Spermatocyte 
Spermatid 
Spermatozoa 
Mitosis 
Spermiogenesis 
Meiosis 
Fig. 2 – A) Cross section of the testis and epididymis. B) Cross section of seminiferous tubule. C) The 
process of spermatogenesis demonstrating the three different phases involved. (Adapted from Rhoades, 
2003 [3]) 
A B 
C 
Epididymis Testis 
Vas deferens 
Seminiferous 
Tubules 
Cross section of 
seminiferous tubule 
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3. Male Infertility  
 About one out of seven European couples suffer from reproductive disorders in the form 
of infertility [26] and 30 to 50% of the cases are of male cause [27,28]. Lately, there has been an 
increase in the awareness of a decline in reproductive health and this tendency is paralleled 
by an increasing pursuit of male infertility biomarkers [29,30,31].  
Clinical Evaluation of Male Infertility 
The diagnostic workup of the infertile male is performed in order to identify the treatable 
forms of the disease, mainly due to hormonal disorders, and non-reversible forms. Therefore, 
the evaluation includes careful examination of medical and reproductive history focused on 
risk factors or behavioral patterns that could affect fertility, a physical examination including 
secondary sex characteristics and genitalia, and semen analysis followed by second level 
exams [27]. Semen analyses, performed according to the WHO parameters, are usually the first 
approach [32]. These analyses provide sperm density, total number, motility, morphology and 
also semen characteristics such as volume, pH and viscosity [27]. The nomenclature for each 
pathological semen profile is presented in Table 2.  
The diagnosis of azoospermia is established when no spermatozoa can be detected on 
high powered microscopic examination of a pellet after centrifugation of the seminal fluid, on 
at least two separate occasions [32]. In those cases where a physical cause of azoospermia 
cannot be identified, such as an obstruction or absence of the vas deferens, second level 
exams should be performed to further elucidate its etiology. These exams may provide 
prognostic value for testicular sperm retrieval, such as the assessment of hormonal levels, 
namely of FSH, testosterone and prolactin. In situations where there is spermatogenic 
impairment, testosterone will be diminished and FSH will be increased, since there is no 
negative feedback by testosterone [27,33].  
Table 2 - Reference values for semen quality parameters in different pathologies by WHO 2010 [32]. 
 Nomenclature Sperm Profile 
 Azoospermia No spermatozoa in ejaculate 
Oligozoospermia 
Sperm concentration below 15 x 106/mL; total sperm number 
below 39 x 106 per ejaculate 
Asthenozoospermia Less than 32% progressively motile spermatozoa 
Teratozoospermia Less than 4% morphologically normal spermatozoa 
Cryptozoospermia 
Spermatozoa absent from fresh preparations but observed in 
a centrifuged pellet 
Aspermia No ejaculate (no or retrograde ejaculation) 
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Classification of Azoospermia 
Azoospermia accounts for 10-15% of male infertility cases and its prevalence is 
aproximatelly 1% among all men [33]. The etiology of severely impaired sperm production can 
relate both to congenital and acquired factors acting at different levels. In essence, 
azoospermia can be further categorized as: 
a) Pre-testicular azoospermia, which includes hypothalamic-pituitary-adrenal axis 
abnormalities having adverse effects on spermatogenesis (secondary testicular failure) [33,34]. 
Examples are hypogonadotrophic hypogonadism and coital disorders (erectile dysfunction, 
ejaculatory disorders as retrograde ejaculation) [27]. 
b) Post-testicular azoospermia, related to obstructive or sub-obstructive lesions of the 
seminal tract, as well as infections and inflammatory diseases of accessory glands and also 
autoimmune infertility [27]. Obstruction resultant of congenital bilateral absence or blockage 
of the vas deferens or epididymis prevents sperm from reaching the urethral meatus [33]. 
c) Non-obstructive azoospermia (NOA) or testicular 
azoospermia, also termed primary testicular failure, which 
encompasses spermatogenesis disorders intrinsic to the testes. 
[33]. NOA can result from reduced spermatogenesis (otherwise 
known as hypospermatogenesis), maturation arrest at early or 
late stages of spermatogenesis, or Sertoli cell-only syndrome 
(SCOS) resulting in complete lack of spermatogenesis (depicted in 
Fig. 3) [27,35]. Most individuals with this phenotype are expected to 
carry genetic defects, discussed in the next section [27]. 
Even though current clinical methods can readily diagnose patients with pre-testicular 
azoospermia, differentiation of NOA from OA is not simple. Men with normal FSH and LH 
levels could present with either NOA or OA, and the only means of differentiating these two 
groups of men is by testicular biopsy [35].  
Genetic biomarkers used to diagnose NOA would benefit azoospermic men, thereby 
eliminating the need for biopsies [35]. Besides, the practice of assisted reproductive 
technology represents a symptomatic therapy which does not address the underlying cause 
for infertility having the risk of transmitting genetic anomalies. Hence, there is a crucial need 
for research in the field of genetics of male infertility to provide the unidentified etiological 
factors and to allow an improved genetic counseling, especially in the most extreme cases of 
spermatogenic impairment, such as NO-Azoospermia [27,36]. 
Fig. 3 - A)Sertoli-cell only 
Syndrome. B)Spermatogenic 
arrest. (Vogt, 1996[8]) 
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3.1. Genetics of Azoospermia 
A large number of genes (approximately 1 in 25 of all mammalian genes) are specifically 
expressed in the male germline, illustrating the complexity of the spermatogenic process [37]. 
Understanding this process became an even greater challenge since the discovery of 
thousands of small non-coding RNAs that have roles on mRNA stability, protein modification 
and protection of the germline. Mutations in thousands of different genes could disturb these 
highly regulated processes, causing infertility, as shown in Fig. 4 [24,37]. In mouse models, 
mutations affecting reproduction impact testis determination, spermatogenesis (meiosis 
defects), sperm function, genital tract development and function, sexual behavior, 
fertilization or early embryonic development [36,37]. 
 
The search for human spermatogenesis genes began in 1976 when Tiepolo and Zuffardi 
reported cytogenetically visible microdeletions in Yq in six azoospermic men [38]. In fact, Yq 
microdeletions are the most frequent known molecular genetic cause of severe 
spermatogenic impairment [27], being detected in 10 to 15% of azoospermic or severely 
oligozoospermic men [6,39]. Most of these deletions occur in nonoverlapping regions of the 
long arm of the Y chromosome (Yq11), designated as the Azoospermia Factor (AZF) region, 
encompassing multiple gene families: AZFa (proximal), AZFb (central), and AZFc (distal), 
depicted in Fig. 5. These regions appear to be critical for germ cell development and 
differentiation and contain several genes that are likely to be necessary for spermatogenesis. 
[33,34] Men with deletions spanning more than one AZF loci are usually azoospermic, as well as 
men spanning an AZFa and AZFb deletion. AZFc deletions are associated with variable 
Fig. 4 – Genetic impact on male fertility. Copy number variations are expected 
to affect mostly spermatogenesis. (Adapted from McLachlan, 2010[6]) 
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Fig. 6 – Karyotype abnormalities occur in about 10% of 
azoospermic men. (Adapted from Mclachlan, 2010[6]) 
phenotypes, from reduced sperm count to azoospermia, due to the presence of autosomal 
homologue and multiple copies [34]. 
Overall, a genetic factor can be diagnosed in about 15% of cases of male factor infertility, 
by applying routine genetic tests [40]. Genetic testing is focused on the most common causes of 
infertility reported so far and includes karyotyping (for detection of 
chromosomal numerical defects) and Yq microdeletions screening. The 
incidence of chromosome structural abnormalities, such as inversions 
and translocations, is 10 times higher (4%) in patients with less than 
10 million spermatozoa/mL than it is in the general population [6,27,33]. 
Among severe oligozoospermic men the frequency of this type of 
alterations increases to 7-8%, reaching the highest values in non-
obstructive azoospermic men – 15 to 16% (Fig. 6) [41].  
Aneuploidies, i.e. chromosomal numerical defects, are characterized by the gain or loss of 
one or more chromosomes and are rarely compatible with life, given the severity of the 
associated phenotype [37]. Klinefelter syndrome (47, XXY), a well characterized aneuploidy 
compatible with life, represents 14% of all cases of azoospermia and severe male factor 
infertility [33,37,42]. 
Mutational analysis of a few spermatogenesis candidate genes has revealed several SNPs 
associated with azoospermia [27,43]. Besides SNPs, structural variants such as CNV affecting 
genes relevant to spermatogenesis could also contribute to infertility [27,44]. Recently, 
Tuettelmann et al. (2011) [44] 
analyzed CNVs in men with 
spermatogenic failure by aCGH 
and suggested that they could 
cause spermatogenic failure by 
an increased number or 
specific distribution of CNVs, 
resulting in defective 
recombination, meiotic failure 
and loss of germ cells.  
Although numerical defects and Y chromosome microdeletions have been thoroughly 
studied and analyzed, a great number of azoospermic cases remain unexplained, termed 
“idiopathic”, and may rely on X-linked and autosomal genomic structural variants [24].  
AZFa 
AZFb 
AZFc 
Yp 
Yq 
Fig. 5 – AZF Regions 
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3.1.1. Candidate Genes on the X chromosome  
The role of X-linked genes in male infertility remains greatly unknown [45]. Nevertheless, 
the X chromosome is of special interest since men are hemizygous for genes located on this 
chromosome. De novo mutations in X-linked genes are expected to have a large effect since 
compensation by a second, normal allele, is not possible. Moreover, recessive X chromosomal 
mutations affecting fertility pathways can be transmitted throughout generations by women 
and may only have a visible effect on the reproductive fitness of a male descendant [34,45]. 
 
Enrichment of Spermatogenesis Genes  
The transcriptional status of the X chromosome changes dramatically during male germ 
cell development. In mammals, sex chromosomes and autosomes are transcriptionally active 
in mitotically dividing spermatogonia and early meiotic (prepachytene) spermatocytes. 
During meiosis, sex chromosomes undergo meiotic sex chromosome inactivation (MSCI, Fig. 
7), and thus are transcriptionally silenced, whereas autosomes are maintained active [46,47,48]. 
In postmeiotic germ cells, sex chromosomes remain transcriptionally repressed.   
Genomic studies have shown that germ cell-specific 
genes are not randomly distributed in the genome, and 
that, in particular, the unique hemizygous and 
transcription status of the X chromosome has shaped its 
germ cell-specific content [49,50]. Thus, the X chromosome is 
enriched for genes expressed prior to meiosis [51]. 
Additionally, Wang et al. (2005) identified genes in 
spermatogonia that were inactivated during meiosis, but 
their expression levels increased again after meiosis was 
completed (post-meiotic genes) [52]. Thus, post-meiotic 
repression of the X chromosome seems incomplete [45]. 
Afterwards, Song et al. (2009) revealed that many X-linked microRNAs escape the 
silencing effects of MSCI in primary spermatocytes, and are transcribed in pachytene 
spermatocytes [53]. MicroRNA (miRNA) molecules are 22 to 24 nucleotide non-coding single-
stranded RNA molecules that bind specifically, in conjunction with a protein complex, to 
complementary messenger RNAs in order to stimulate its degradation or repress its 
translation [7,24,54]. Indeed, reproduction is controlled not only by protein coding segments of 
X         Y X      Y 
Fig. 7 – MSCI – Unpaired 
regions of the sex chromosomes 
are transcriptionally silenced. 
Dotted lines indicate pairing ate 
the PARs. (Adapted from Khanhi, 
2005 [5]) 
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the genome but also by noncoding regions, including microRNAs [24]. The fact that X-linked 
microRNAs escape MSCI indicates their possible role in the MSCI process itself, or that they 
might be essential for post-transcriptional regulation of autosomal mRNAs during the late 
meiotic and early postmeiotic stages of spermatogenesis [53]. Although deletions in 
microRNAs are yet to be uncovered in infertile individuals, the microRNA pathways are 
crucial for general growth and differentiation [24].  
Furthermore, about 1098 genes are estimated to be located on the human X chromosome. 
Of these, nearly 10% are expressed simultaneously in testicular tissue and various cancers. 
These genes, often multicopy, are referred to as the cancer-testis (CT) antigens and can be 
further subdivided into several gene families [55]. CT-antigens may be related to 
spermatogenesis due to their unusual restricted expression during different discrete events 
of spermatogenesis, such as cell cycle progression, meiosis and spermiogenesis. Many of the 
developing germ cells, including spermatogonia, spermatocytes, round and elongating 
spermatids only express these genes transiently, at specific steps in spermatids or during 
spermiogenesis and differentiation [34,56,57]. The MAGE (Melanoma Antigen) and GAGE (G 
Antigen) are the largest and best known CT families. The function of most of these genes is 
unknown, but a role in the regulation of the cell cycle or apoptosis has been suggested. 
Besides these CT genes, other genes with a testis-specific or-enriched expression pattern 
have been identified on the X-chromosome [49,57]. In fact, Wang et al. (2001) identified an X-
linked CT gene, TAF7L (TATA box binding protein- associated factor 7 like) which is thought 
to play a critical role in the promotion of synapsis and regulation of crossover given their 
disruption caused segregation defects and azoospermia [49].  
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3.1.2. Autosomal Contribution - WT1 Gene  
The first step in the establishment of reproductive fitness in mammals is individual sex 
determination [58]. Many autosomal genes have a role in the differentiation process of the 
bipotential gonad, including the Wilms’ Tumor 1 (WT1) gene [24]. 
 
Alternative Splicing Isoforms  
The Wilms’ Tumor 1 (WT1) gene, on Fig. 8, spans approximately 50 kb and is located at 
11p13. This gene contains 10 exons which encode a protein with a C-terminal zinc-finger (ZF) 
domain, spanning exons 7-10, involved in DNA- and RNA-binding. The proline-glutamine rich 
N-terminus encloses a self-association domain and an RNA recognition motif. Post 
transcriptional modifications (such as RNA editing and alternative splicing) of WT1 pre-
mRNA gives rise to at least 24 protein isoforms, each of which with a distinct contribution to 
WT1 biological functions. Indeed, some isoforms cooperate in different cellular and 
developmental functions and, therefore, it is expected that balanced expression among 
isoforms is critical for proper WT1 function [59,60,61,62,63].  
There are four predominant isoforms of WT1, originating from two alternative splice 
sites. The insertion of exon 5 (only present in mammals) adds 17 amino acids between the N- 
and C-terminus of the WT1 protein, and it has been demonstrated that mice homozygous for 
WT1 lacking exon 5 have no salient phenotype [62]. On the other hand, the usage of an 
alternative splice donor site at the end of exon 9 results in the addition of three amino acids, 
KTS (lysine-threonine-serine), between zinc-fingers 3 and 4. The +KTS/-KTS protein ratio 
seems to be constant in all cells, with a predominance of the +KTS form in 60% of the 
transcripts. The KTS insertion destabilizes the interaction of the ZF region with DNA, thereby 
Fig. 8 – WT1 Gene with 10 exons in blue, numbered; Alternative splicing in light blue (Exon 5 and 
KTS insertion between exons 9 and 10); Domains in yellow, red (transcription repression domains) and 
green (transcription activation domain); Alternative start sites represented by yellow triangles.  
 
WT1 Gene  
1 2 3 4 5 6 7 8 9   10 
Self Association Domain 
Rep Activation Rep 
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shifting the activity of this isoform towards post-transcriptional RNA processing. By contrast, 
WT1-KTS is associated with the transcriptional regulation (activation or repression) of 
multiple target genes [61,62,63,64,65,66]. Recently, Dallosso et al. (2004) reported a shorter 
transcript - AWT1 - originated from a non-AUG translational start site within intron 1 which 
creates an alternative exon (exon 1a), producing a protein with unknown functional 
significance [67]. Furthermore, besides the major initiator site AUG, WT1 comprises an 
alternative start site at an in-frame CUG codon upstream of the first, resulting in larger 
protein isoforms. Internal translational initiation at an in-frame AUG generates, downstream 
of the traditional AUG, results in smaller WT1 protein isoforms (Fig. 8) [66,68,69].  
As aforementioned, WT1 acts as a transcription factor and this occurs through the 
interaction of its activation and repression domains, represented in Fig. 8, with its targets. 
This activity is thought to be modified by dimerization of WT1 with other proteins 
(heterodimerization) or even with itself (homodimerization), at the N-terminal self-
association domain [63,65]. 
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Gonadal Development and Maintenance  
Male sex development comprises three stages: 1) initial undifferentiated stage; 2) a 
gonadal differentiation stage; 3) an external genitalia differentiation stage (see Fig. 9). Stage 1 
initiates with the differentiation of the gonadal ridge from the mesonephric mesoderm and 
the coelomic epithelium, the common precursor of the gonads and kidneys, and this process 
is stimulated by WT1 and SF1 (or NR5A1, an orphan nuclear receptor) [28,65,70]. WT1 is initially 
expressed during embryonic development in the urogenital ridge. Moreover, the main WT1 
isoform reported to participate in male sexual development is the one lacking the KTS 
insertion which has the ability to stimulate SF1 [28,70]. 
Next, in Stage 2, the presence of SRY triggers testicular differentiation, driving the 
gonadal ridge to the male pathway, upregulating SOX9. This crucial step is positively 
regulated by WT1 and SF1, and antagonized by both WNT4 and DAX1 [70,71,72,73,74,75]. 
From the gonadal ridge, the Müllerian ducts are formed in the undifferentiated gonads of 
male and female embryos and the hormones produced by the developing fetus decide the 
male or female sex development. In Stage 3, Sertoli cells secrete Anti-Müllerian Hormone 
(AMH), responsible for the regression of the female Müllerian ducts. AMH expression is 
triggered by SOX9 and enhanced by WT1 and SF1 [70,76]. However, antagonistic stimuli from 
DAX1 interaction with SF1 represses the WT1-SF1-activated transcription of the AMH gene in 
a dosage-dependent manner, suggesting that the relative levels of WT1 and DAX1 may 
determine the transcriptional activation of the AMH gene [65,75]. Furthermore, testosterone 
produced in Leydig cells binds to the androgen receptor in Wolffian ducts and promotes their 
differentiation into the components of the male gonaducts [70].  
In the absence of SRY, the testis does not form and AMH and testosterone are not 
secreted. Consequently, the Wolffian ducts passively regress and differentiation of the 
Müllerian ducts into female reproductive system occurs [65]. Besides, there is evidence 
suggesting that WT1 stimulates the expression of SRY gene, the main testis-determining 
factor. Therefore, WT1 performs an essential role in the male gonadal differentiation pathway 
and, in fact, homozygous knock-out mice do not develop gonads [66]. 
In the embryo, WT1 expression is also observed in spleen, liver, thymus, brain and spinal 
cord and in the lining of the abdominal cavity (mesothelium). Throughout life, WT1 
expression is maintained in glomerular podocytes in the kidney and in Sertoli cells, where it 
has a maintenance function. Chang et al. (2008) reported that WT1-dependent suppression of 
WNT/β-catenin signaling in Sertoli cells is essential for the normal development of 
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primordial germ cells as stabilization of β-catenin would cause delayed cell cycle progression 
and result in germ cell deficiency [73].  
 
  
Fig. 9 – Male Sexual Differentiation Process. Green – Stimulation. Red – Repression. 
Stage 1 
 Wolffian Duct development 
 Male external genitalia 
 Müllerian Duct 
regression 
Mesonephros 
Coelomic Epithelium 
Gonadal Ridge 
WT1-SF1 SRY 
SOX9 
T
e
s
ti
s
 
Testosterone 
Leydig Cells Sertoli Cells 
AMH 
WNT4 
DAX1 
Stage 2 
Stage 3 
Introduction 
Page  22 Molecular Biomedicine 2012 
 
WT1-Associated Syndromes  
Several clinical phenotypes have been associated to abnormalities in the WT1 gene. 
However there are three main syndromes, namely WAGR, Denys-Drash and Frasier 
Syndromes, that almost invariably are associated with constitutional WT1 mutations, as 
presented in Table 3 [77,78].  
 
Table 3 - WT1-associated Syndromes 
 
 Genotype Consequences Clinical Phenotype 
W
A
G
R
  
S
y
n
d
ro
m
e
 
 
Large 11p13 deletions: 
 WT1 gene:  
genitourinary features. 
 PAX6 gene: aniridia. 
 
The tumors usually carry 
intragenic somatic mutations 
in the remaining WT1 allele. 
 
 
Individuals with a constitutional 
WT1 deletion present a high 
risk of developing Wilms’ 
Tumor (>20%) and should be 
monitored. 
 
 
 Wilms’ tumor 
 Aniridia 
 Genitourinary anomalies 
 Mental retardation 
D
e
n
y
s-
D
ra
sh
  
S
y
n
d
ro
m
e
 
 
Heterozygous point mutations 
within the exons coding the ZF 
region of WT1. 
 
DDS mutant WT1 proteins fail 
to bind DNA and act in a 
dominant negative fashion by 
forming homodimers with 
normal WT1 protein.  
 
Prevents WT1 physiological 
activity. 
 
 
DDS triad: 
 Mesangial sclerosis 
(nephropathy) 
 Genital abnormalities 
(mild to XY pseudo-
hermaphroditism) 
 Wilms’ tumor 
F
ra
si
e
r 
 
S
y
n
d
ro
m
e
 
 
Constitutional intronic 
mutations in the second donor 
splice site of intron 9, on one 
WT1 copy. 
 
Prevention of the production of 
the KTS-containing isoforms. 
There is a shift in the KTS 
isoform ratio, leading to an 
imbalance of WT1 isoform 
functions, rather than a 
formation of mutant protein. 
 
 XY pseudo-
hermaphroditism 
 Glomerulonephropathy 
 Usually do not develop 
renal tumor 
 
Besides the syndromic features, there is also a broad range of non-syndromic phenotypes 
associated with WT1 defects. Usually, a modification in WT1 is accompanied by genitourinary 
dysgenesis, defined as isolated or combined cryptorchidism, penoscrotal hypospadias, 
hypoplastic testes and renal disorders as nephropathy or Wilms’ tumor [63].  
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Recent studies suggest that although the phenotypic expression of WT1 is variable, a 
certain genotype-phenotype correlation regarding the degree of gonadal dysgenesis, 
nephropathy, and Wilms’ tumor can be found. This variation depends on the affected exons 
and, thus, the altered protein domains. Patients with C-terminal missense or nonsense 
mutations usually display severe gonadal dysgenesis and/or nephropathy. This more severe 
phenotype is suggested to be either the result of the dominant negative action of 
heterozygous WT1 missense mutations and profoundly impaired WT1 function during 
development or the formation of a truncated dysfunctional protein [62,63,77,79,80,81,82].  
On the other hand, N-terminal WT1 modifications are expected to have a milder impact 
on its physiological function, as the DNA-binding domain would remain intact. However, most 
of the reported mutations affecting the initial exons of this gene result in truncated proteins 
and are associated with the presence of renal tumor and genitourinary abnormalities. 
Nevertheless, Kohler et al. (2004) identified a missense mutation in exon 2, resulting in 
genitourinary defects as micropenis, hypospadias and cryptorchidism without renal tumor 
[83]. 
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Aims 
The work developed under the scope of this dissertation is comprised within the Project 
"Search for genomic structural variants in azoospermia: a study in the Portuguese 
population" led by Alexandra Lopes (IPATIMUP), initiated in May 2010. Previously, samples 
from 166 Portuguese men with non-obstructive azoospermia and 5 with severe 
oligozoospermia had been screened to exclude the presence of Y chromosome microdeletions 
or karyotype abnormalities (46, XY) by routine methods. An integrated genome-wide analysis 
of SNP genotypes and copy-number sensitive probes on Affymetrix SNP Array 6.0 allowed the 
identification of candidate regions harboring CNVs that were restricted to patients, using the 
genotypes of 1000 males from the Wellcome Trust Case Control Consortium (WTCCC2) as 
control data. The present study will focus on patient-specific deletions found in this study 
harboring genes involved in spermatogenesis pathways, which are good candidates for 
underlying the spermatogenic impairment observed in these patients.  
In the first part of the study we focus on X-linked deletions which, as aforementioned, 
will result in nullizygosity in men. Thus, we aim to validate, by aCGH and molecular genetics 
techniques such as PCR and Sanger Sequencing, all patient-specific X-linked deletions 
potentially disrupting genes or other transcribed sequences. Besides, an additional goal is to 
characterize the deletions’ breakpoints by aCGH analysis in order to understand the 
mutational mechanisms involved and to determine with precision the sequences affected by 
the deletion.  
In the second part of our study we address the involvement of genetic defects on the WT1 
gene in azoospermia, motivated by the discovery of a large deletion (approximately 1 Mb) at 
11p13 in a non-syndromic patient of our cohort analyzed on the Affymetrix 6.0 array. To 
date, reported deletions on 11p13 are associated with complex syndromes or isolated 
genitourinary anatomic malformations, such as hypospadias and cryptorchidism as well as 
nephropathy or renal tumor. Our aim was, thus, to confirm the deletion by MLPA and to 
characterize the deletion breakpoints by Long-Range PCR and Sanger Sequencing.  
Additionally, in order to explore the association of WT1 germline mutations with severe 
spermatogenic impairment in otherwise healthy men, a cohort of 40 azoospermic patients 
was screened for coding mutations, by exon sequencing. We aimed at testing the hypothesis 
that unknown mutations in the WT1 gene not involving the DNA binding domains, but still 
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interfering with the function of the protein, could be associated to a less severe phenotype 
such as isolated (non-syndromic) spermatogenic impairment.  
 Rare Structural Variants in Severe Spermatogenic Impairment 
 
Catarina Morais Seabra  Page  27 
 
Material and Methods 
Previous Work – Affymetrix SNP Array 6.0 
Under the scope of the FCT funded project "Search for genomic structural variants in 
azoospermia: a study in the Portuguese population", DNA samples of the 166 NOA and 5 
oligozoospermic males (extracted by salting out, from peripheral blood leukocytes) were 
collected at the Genetics Department from INSA-IP and at the Genetics Service from FMUP 
(where routine diagnosis for male infertility is established) and were run in Affymetrix 
Genome-Wide Human SNP Array 6.0. These are hybrid genotyping arrays designed to capture 
information on SNPs (single nucleotide polymorphisms) and CNVs (copy number variants) 
simultaneously. The detection of rare copy number variants through SNP analysis is 
comparable to a mutation screen using high resolution aCGH, with the advantage of providing 
simultaneously genotype data on 906,600 single nucleotide polymorphisms (SNPs) and more 
than 946,000 probes for the detection of copy number variation 
(http://www.affymetrix.com).   
In SNP genotyping platforms, a signal intensity measure is summarized for each allele of a 
given SNP marker [84]. For CNV detection, the signal intensities of the match and mismatch 
probes are compared with values from another individual (or group of individuals) and the 
relative copy number per locus is determined [10]. 
Analysis of signal intensities across the genome can then be used to identify regions with 
multiple SNPs that support deletions or duplications. The Log R Ratio (LRR) is a normalized 
measure of the total signal intensity for two alleles of the SNP. The B Allele frequency (BAF) is 
a normalized measure of the allelic intensity ratio of two alleles. The combination of LRR and 
BAF can be used to infer copy number changes in the genome. In the presence of a deletion, 
there is a decrease in LRR values and a lack of heterozygotes in BAF values [84]. 
In spite of the accuracy and high resolution of this platform, all array based genome-wide 
analyses are subjected to false positive results and require further validation. Hybridization 
to an array requires that the DNA is first digested with a restriction enzyme and ligated with 
adapters and then the smaller fragments amplified using universal primers to reduce the 
complexity of the hybridization. This procedure raises the possibility of amplification bias of 
different regions of the genome and detection of changes reflecting differences in restriction 
digestion patterns between individuals rather than in true copy number. The detection of 
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CNVs smaller than 20 kb is particularly prone to error, since a smaller number of probes will 
show hybridization intensity changes.  
The integrated analysis of SNP genotypes and copy-number sensitive probes on the 
Affymetrix 6.0 SNP array allowed the identification of candidate regions harboring CNVs 
restricted to azoospermic patients. In the present study we have focused on the validation 
and characterization of the most promising deletions found in the first stage of the 
aforementioned project by complementary techniques.  
 
Selection of Candidate Deletions 
The CNVs identified through the analysis of the Affymetrix 6.0 platform were thoroughly 
characterized in silico using online Bioinformatics tools, namely the UCSC Genome Browser 
according to the assembly of March 2006 (NCBI36/hg18). This analysis consisted in the 
identification of deleted regions spanning genes and other transcribed sequences, as well as 
their putative regulatory regions, which may represent good candidates for a role in 
spermatogenesis. Particular emphasis was given to those rearrangements located on the X 
chromosome as they would result in nullizygosity for the genes within the deleted region. 
Thus, we chose the most interesting X-linked deletions to be confirmed by PCR and Sanger 
Sequencing and/or aCGH. Additionally, a large autosomal deletion on 11p13 was selected for 
further characterization (Table 4).  
Table 4 – Characteristics of the patient specific deletions chosen for further analysis and validation. 
 Locus Gene Length (bp) Position Phenotype 
D
e
le
ti
o
n
s 
Xq22.1 TAF7L 6.610 chrX:100416094-100422703 NO-Azoospermia 
Xp11.4 CXorf27 7.688 chrX:37734603-37742290 
Severe 
Oligozoospermia 
Xq21.1 RPS6KA6 9.567 chrX:83237920-83247486 NO-Azoospermia 
Xq28 hsa-miR-4330 10.381 chrX:150079516-150089896 NO-Azoospermia 
Xq25 STAG2 20.601 chrX:123034686-123055286 Sertoli cell-only 
Xq26.3 CXorf48 41.124 chrX:134083698-134124821 NO-Azoospermia 
Xq28 MAGE-A8 106.015 chrX:148683405-148789419 NO-Azoospermia 
11p13 WT1 1.034.890 chr11:32345278-33380167 NO-Azoospermia 
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Polymerase Chain Reactions (PCR) 
PCR conditions varied according to the target amplification product. PCR primers 
(Supplementary Tables 9 and 10) were designed using Genius Software, which applies 
Primer3 algorithms (http://primer3.sourceforge.net/). The generated primers followed 
preset standards, namely melting temperature (Tm) close to 60° C, a GC content of 
approximately 50% and hairpin and primer-dimer values below 3. Additionally, OligoCalc 
was used to check for hairpin formation while the tools BLAT (available at UCSC Genome 
Browser) and BLAST (available at NCBI website) were used to avoid primers with high 
identity to non-target sequences which could lead to cross-hybridization and nonspecific PCR 
products. Finally, the “In Silico PCR” tool from the UCSC Genome Browser was used check for 
all the possible amplification products originated using each pair of primers. 
Different primer design strategies were used, according to the amplification target and 
chromosomal location. For both deletions on X chromosome and on 11p13, two types of 
primers were tested: 1) flank primers were designed by placing one of the primers inside the 
deletion and the other outside it and 2) across-deletion primers were both located outside 
the deletion, one on each flank, encompassing the entire deleted area. Both flank and across-
deletion primers were placed externally  to the outermost SNP within the deleted regions 
and/or the first non-deleted SNP(s)/CNV probe(s) detected by the Affymetrix SNP Array 6.0, 
as depicted in Fig. 10.  
Given that several X-chromosomal loci were flanked by highly repetitive sequences, 
which represent a great difficulty for specific primer design, another strategy was adopted. 
This simpler strategy involved the use of internal primers within the putative deletion, in 
order to confirm presence/absence of the targeted sequence in the patient and two male 
controls (as all our patients are males the presence of the deletion would preclude any 
amplification). Those deletions for which no amplification was obtained were subsequently 
validated by aCGH, performed at OGT (Oxford Gene Technology, Oxford, UK). 
C - Internal 
A – Across-deletion  B - Flanking 
Fig. 10 – Primer design strategies developed. 
Grey vertical lines represent the SNPs 
detected in the SNP array. Arrows represent 
forward and reverse primers. 
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Depending on the size of the PCR products, different Protocols were used. For smaller 
products (RPS6KA6, hsa-miR-4330, STAG2 and TAF7L internal fragments) Qiagen MasterMix 
(Qiagen, Hilden, Germany) was used.  
 
 
For intermediate size products, as those originated from some internal primers (TAF7L, 
MAGE-A8, WT1), flanking primers (CXorf27) or across primers (hsa-miR-4330), MyTaq Mix 
(Bioline, London, UK) was applied. 
 
 
Qiagen MasterMix HSTaq  - PCR Setup (final volume of 10 μL) 
Reagents  Temperature (°C) Time Cycles 
 
 5  µL Mix (2x) 
 0,5  µL Forward Primer (10 μM) 
 0,5  µL Reverse Primer (10 μM) 
 3  µL H20 
 1  µL DNA Template (30 ng/μL) 
 
94 15 min 1 
94 30 s 
35 60 30 s 
72 30 s 
72 7 min 
1 
12 ∞ 
Bioline 2x MyTaq – PCR Setup (final volume of 10 μL) 
Reagents  Temperature (°C) Time Cycles 
 
 5 µL Mix (2x) 
 0,5  µL Forward Primer (10 μM) 
 0,5  µL Reverse Primer (10 μM) 
 3  µL H20 
 1  µL DNA Template (30 ng/μL) 
94 5 min 1 
94 30 s 
35 
60 30 s 
72 
30 s  
(or 60s/kb) 
72 10 min 
1 
12 ∞ 
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ExpandLong Range dNTP Mix (Roche, Basel, Germany) was used in those cases with 
expected PCR products above 3kb (CXorf48 flank primers and WT1 across-deletion).  
 
 
 
Annealing temperatures were adapted to the characteristics of each primer pair. 
Template DNA concentration was measured in NanoDrop ND-1000 (NanoDrop Technologies, 
Wilmington, DE, USA). PCRs were carried out in Applied Biosystems Thermal Cycler (Applied 
Biosystems, Foster City, CA).  
 
 
 
  
Roche ExpandLong Range dNTPack – PCR Setup (final volume of 25 μL) 
Reagents  Temperature (°C) Time Cycles 
 
 5 µL Buffer with MgCl2 (1x) 
 1,25  µL dNTP Mix (500 μM) 
 0,75 µL Forward Primer 0,3 μM 
 0,75 µL Reverse Primer 0,3 μM 
 0 – 12% DMSO 
 0,35 µL Enzyme Mix (5 U/μL) 
 Add to 25 μL of H2O 
 ≤ 250 ng DNA Template 
92 2 min 1 
92 10 s 
10 58 15 s 
68 60s/kb 
92 10 s 
25 
58 15 s 
68 
60s/kb + 
20s/cycle 
68 7 min 
1 
12 ∞ 
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Gel Electrophoresis and Staining 
PCR products were separated on acrylamide and/or agarose gels and were subjected to 
electrophoresis at 250 v and 85 v, respectively.   
Acrylamide 1x 
 3 mL Acrylamide 
 25 mL Gel Buffer 4x  
(1,5 M Tris-HCl Buffer, pH 8.8) 
 20 mL Acrylamide: Bisacrylamide (19:1, 40%)  
 7 mL Glycerol 
 43 mL H20 
 170 μL APS 
 0,250 g APS 
 10 mL H20 
 7 μL TEMED 
 
 
Following electrophoresis, agarose gels were observed under UV light in Molecular 
Imager® ChemiDoc™ XRS Imaging System (Bio-rad, Hercules, CA, USA), whereas the 
acrylamide gels were stained by the silver staining process described in Table 5 below. 
 
Table 5 - Silver staining protocol. 
 
Reagents Time 
S
il
v
e
r 
S
ta
in
in
g
 
1. Ethanol (10 %)  
(25 mL + 225 mL distilled water) 
10 min 
2. Nitric Acid (1 %)  
(2,5 ml + 247,5 ml distilled water) 
5 min 
3. Wash with distilled water 2 x 10 s 
4. Silver Nitrate (0,2 %)  
(0,5 g + 250 mL distilled water) 
20 min 
5. Wash with distilled water 2 x 10 s 
6. Sodium Carbonate (0,28 M) + Formaldehyde (0,02 %)  
(3 g carbonate + 100 mL distilled water + 1 mL formaldehyde) 
- 
7. Acetic Acid (10 %) 2 min 
8. Wash with distilled water 2 x 10 s 
Agarose 1x 
 0,5 g Agarose 
 50 mL TBE 
 5 μL RED 
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Sanger Sequencing 
Some of the PCR products were sequenced afterwards, by Sanger Sequencing, for further 
confirmation and characterization. This method, also referred to as dideoxy sequencing or 
chain termination, is based on the use of dideoxynucleotides (ddNTP’s) in addition to the 
normal nucleotides (dNTP’s) found in DNA. Dideoxynucleotides are similar to regular 
nucleotides except they contain a hydrogen group on the 3’ carbon instead of a hydroxyl 
group (OH). These modified nucleotides, when integrated into a sequence, prevent the 
addition of further nucleotides as a phosphodiester bond cannot form between the 
dideoxynucleotide and the next incoming nucleotide and, thus, the DNA chain is terminated. 
This process includes four main steps: 
 
 
 
1) ExoSAP reaction  
(removal of unincorporated primers and nucleotides from the PCR product) 
Reagents Temperature (°C) Time Cycles 
 1,8 μL PCR Product 
 0,9 μL ExoSAP 
37 15 min 
1 80 15 min 
12 ∞ 
2) Sequencing reaction  
(incorporation of  ddNTP’s) 
Reagents Temperature (°C) Time Cycles 
 
 0,5 μL BigDye Mix 
 0,75 μL Buffer 
 0,75 μL PCR Product 
from ExoSAP reaction 
96 2 min 1 
96 15 s 
35 55 5 s 
60 2 min 
60 10 min 
1 
12 ∞ 
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4) Capillary Electrophoresis 
The purified products were run in the automatic sequencer ABI 3130XL (Genetic 
Analyser 3000®, Applied Biosystems) and analyzed using Geneious Software [2].  
 
 
Multiplex Ligation-dependent Probe Amplification (MLPA) 
MLPA was performed using the SALSA MLPA P219 PAX6 probemix kit containing specific 
probes for 11p13-14 locus, presented on Fig. 11, commercially available from MRC-Holland 
(Amsterdam, the Netherlands; www.mlpa.com/pages/indexpag.html). This probemix 
contains one probe for each exon of the PAX6 gene with the exception of exon 7 and 13 and 
two for exon 2a. Furthermore, the probemix contains several probes for WT1 exons, as well 
as probes for two hypothetical genes, LOC645981 and LOC646008, and the gene RCN1 which 
are all located in the region between PAX6 and WT1. The probemix also includes probes for 
the genes BDNF, FSHB, DCDC1, and ELP4 flanking PAX6 telomeric and probes for the genes 
HIPK3, LMO2, EHF, and CD44 centromeric to WT1. Three probes are present for the SOX2 
gene and, in addition, 7 reference probes are included in this probemix, detecting several 
different autosomal chromosomal locations.  
3) Sephadex Purification  
(removal of unincorporated primers and  ddNTP’s  from sequencing reaction)  
Reagents per Sample Steps 
 
 5 μL PCR Product 
 750 μL Sephadex 
 9  μL Formamide 
  
 
 
 
 Place columns in 2 mL tubes 
 Add 750 μL of sephadex in each column 
 Centrifuge at 4400 rpm, for 4 minutes 
 Place columns in new 1,5 mL tubes, after  
 discarding the liquid left in the 2 mL tubes 
 Add the totality of the sample (5 μL) in the center  
 of the sephadex column 
 Centrifuge at 4400 for 4 minutes 
 Remove column and add 9-10 μL of formamide to the 
sample, in order to increase the stability of the single 
stranded DNA molecules, for subsequent capillary 
electrophoresis. 
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The reaction procedure followed the manufacturer’s recommendations using 200 ng of 
genomic DNA per reaction. MLPA products were afterwards separated on an ABI Prism 3500 
Genetic Analyzer (Applied Biosystems, Foster City, CA) by automated capillary 
electrophoresis, using GeneScanTM ROXTM as internal size standard. Fragment analysis was 
performed using GENEMAPPER software v4.0 (Applied Biosystems, Foster City, CA). The 
normalization method used was the block normalization method in which the final ratio is 
obtained by dividing the peak area of each amplification product by the total area of the 
reference probes only. 
 
 
 
Array Comparative Genomic Hybridization (aCGH) 
Array CGH involves labeling a reference genome and a testing genome with different 
fluorescent dyes which are subsequently hybridized together to the array. The resulting 
fluorescence ratio is then measured, clone by clone, and plotted relative to each clone’s 
position in the genome. The resolution of aCGH is determined by size and number (density) 
of sequences spotted onto the array. Oligonucleotide probes provide the highest resolution 
for array CGH [10,84,85]. This analysis was performed by outsourcing at OGT (Oxford Gene 
Technology, Oxford, UK). An Agilent 60k Custom Array was designed in order to contain a 
high number of probes in the regions for CNV validation and breakpoint refinement. The male 
pooled genomic DNA (Promega) was used as reference. CytoSure Software (Oxford Gene 
Technology, Oxford, UK) was used for posterior data analysis. 
  
Fig. 11 - MLPA P219 PAX6 kit probes represented by orange triangles, demonstrating the genes 
along 11p13-14 targeted by this approach (UCSC Genome Browser). 
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Functional Biological Pathway Approach – Bioinformatics Tools 
The gene sequences annotated in UCSC Genome Browser and Ensembl were used as 
references. Several web-based genome/protein annotation databases and browsers were 
used to explore the validated rare variants. GermOnline 4.0 gateway 
(http://www.germonline.org/), a cross-species microarray expression database focusing on 
germline development, meiosis and gametogenesis, which provides information on high-
throughput expression data obtained from whole-genome high-density oligonucleotide 
microarrays (GeneChips) [86] was used to check for germline expression of our candidate 
genes. CTDatabase (http://www.cta.lncc.br), which comprises information about each 
cancer-testis (CT) gene and its gene products, was used to confirm MAGE-A8 gene function. 
To predict hsa-miR-4330 targets, microrna.org (www.microrna.org) was used. These 
predictions are obtained using mirSVR, a regression model that computes a weighted sum of 
a number of sequence and context features of the predicted miRNA::mRNA duplex The 
mirSVR score provided at mircrorna.org utilizes miRanda prediction rules such as seed-site 
pairing, site context, free-energy, and conservation and are calibrated to correlate linearly 
with the extent of downregulation [87].  
Expression levels of hsa-miR-4330 target genes in the germline were obtained at 
GermOnline and their function was characterized using Gene Ontology 
(http://geneontology.org/). The protein domains encoded by these genes were identified 
using Ensembl, ExPASy (SIB Bioinformatics Resource Portal - http://expasy.org/) and 
UniProt (Universal Protein Resource - http://www.uniprot.org/uniprot/).  
 
WT1 Mutation Screening in 40 Azoospermic Patients  
From the initial cohort of idiopathic azoospermic patients, 40 individuals were randomly 
chosen for a mutation screening of WT1 exons, including 2 samples of patients presenting 
cryptorchidism and 2 samples from patients with varicocele and hydrocele. WT1 exons from 
these patients were sequenced by Sanger Sequencing and then aligned to Ensembl reference 
gene sequence - ENSG00000184937, using Geneious Software [2]. 
The 1000 genomes Project [88] was used to check for all the reported variants in the 
screened regions.  This is an international collaboration to produce an extensive public 
catalog of human genetic variation, including SNPs and structural variants that have 
frequencies of at least 1% in the populations, and their haplotype contexts, supporting 
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genome-wide association studies and other medical research studies. The samples are mostly 
anonymous and have no associated medical or phenotype data.  We downloaded the phase 1 
release v3 data which generated genome sequencing data of 1092 individuals from five major 
populations groups – West African, European, American, and East and South Asian – covering 
a total of 14 populations (Supplementary Table 8).  
In order to predict the impact of a non-synonymous substitution found in our cohort of 40 
patients, PolyPhen-2 tool [89] for the prediction of functional effects of human nsSNPs 
(http://www.bork.embl-heidelberg.de/PolyPhen/) was performed, using as reference the 
Ensembl WT1 Protein - ENSP00000331327 and/or the respective transcript sequence 
ENST00000332351. This transcript comprises all 10 WT1 exons (3122 bp) and initiates with 
the upstream CUG codon. PolyPhen-2 is an automatic tool for prediction of possible impact of 
an amino acid substitution on the structure and function of a human protein. This prediction 
is based on a number of features comprising not only the amino acidic sequence but also 
phylogenetic (conservation) and protein structural information. The result obtained for each 
substitution falls in four possible predictions for the effect of the substitution:  “benign”, 
“possibly damaging”, “probably damaging”, or “unknown”. 
Two pairs of datasets were used to train and test built-in PolyPhen-2 prediction models. 
The first pair, HumDiv, was compiled from all damaging alleles with known effects on the 
molecular function of the protein causing human Mendelian diseases, present in the 
UniProtKB database, together with differences between human proteins and their closely 
related mammalian homologs, assumed to be non-damaging. The second pair, HumVar, 
consisted of all human disease-causing mutations from UniProtKB, together with common 
human nsSNPs (MAF>1%) without annotated involvement in disease, which were considered 
non-damaging. 
 Rare Structural Variants in Severe Spermatogenic Impairment 
 
Catarina Morais Seabra  Page  39 
 
Results 
Xq21.1, Xq25, Xp11.4 and Xq22.1 Deletions Not Validated 
Even though the Affymetrix 6.0 analysis indicated the presence of deletions at Xq21.1, 
Xq25, Xp11.4 and Xq22.1, encompassing RPS6KA6, STAG2, CXorf27 and TAF7L, respectively, it 
was possible to amplify these sequences from the genomic DNA of the patients suspected to 
carry each of these deletions, as presented in Fig. 12. Moreover, the DNA aliquots loaded on 
the SNP Array plate were also tested for further confirmation. For all cases, except Xp11.4 
(CXorf27), both the patient sample from the original stock and the aliquot on the plate used 
for the array hybridization showed an identical amplification pattern. For the case suspected 
to contain a deletion on Xp11.4, the expected fragment of 972 bp could only be obtained with 
the patient stock sample using a 5’ flanking primer pair. While the patient sample from the 
SNP array plate failed to amplify it is possible that the amount of DNA in the plate could have 
not been sufficient to allow amplification and, consequently, the results from the plate were 
inconclusive. Through this analysis we excluded the existence of a deletion at these loci. 
 
The TAF7L gene at Xq22.1 is a paralogue of the somatic transcription factor TFIID 
subunit TAF7 on chromosome 5 [57]. As these genes have high sequence identity, which could 
result in false positive cross-amplification, the internal TAF7L PCR products obtained from 
the patient sample were sequenced to verify correct amplification from the target X 
chromosome locus. Indeed, the obtained sequences were aligned to the reference human 
254 bp 
RPS6KA6 
  C1  C2   PS  PP 
122 bp 
C1  C2    PS  PP 
STAG2 
247 bp 
248 bp 
CXorf27 
972 bp 
C1  C2   PS   PP 
180 bp 
235 bp 
TAF7L 
C1 C2 PS   C1 C2 PS PP 
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Fig. 12 – X-linked PCR products were obtained using both control and patient samples.  
C1 – Control sample 1; C2 – Control sample 2; PS – Patient sample from stock; PP – Patient sample 
from array plate. 
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genome (Mar. 2006 (NCBI36/hg18)) using a BLAT search (http://genome.ucsc.edu/cgi-
bin/hgBlat), which presented a hit with 100% nucleotide identity to the TAF7L gene at 
Xq22.1, on Fig. 13. 
 
aCGH Excludes Xq26.3 (CXorf48) Deletion  
The Xq26.3 flanking primers generated the 
expected fragment of 9.329 bp in the control 
samples, whereas the patient sample produced 
a very weak band with the size expected for the 
amplification products, presented in Fig. 14. 
However, this result could not be replicated 
and subsequent attempts to perform this 
reaction were unsuccessful. Electrophoresis 
was carried out on both acrylamide and 
agarose gels for additional confirmation. 
Across-deletion primers were also tested but 
were also unsuccessful in spite of many 
attempts with different PCR conditions.  
Array CGH analysis of Xq26.3 with high resolution for this locus was performed as an 
additional confirmation method (Fig. 15). The aCGH analysis shows conclusive results with 
log2 intensity ratio of test to reference sample approximately equal to 0 for the probes 
encompassing the putative deletion which excludes the possibility of a deletion. 
  
Fig. 15 - aCGH analysis of X-chromosome shows a log2 ratio ≈ 0 in Xq26.3, indicating no deletion. 
Acrylamide 
C1  C2    PS             C1   C2    PS  
9.329 bp 
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Fig. 14 – Flanking PCR products show 
inconclusive band from patient sample. C1 – 
Control sample 1; C2 – Control sample 2; PS – 
Patient sample from stock. 
Fig. 13 - BLAT (UCSC) shows 100% identity of TAF7L internal fragment to its locus on the X 
chromosome. 
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Xq28 Nullizygosity Supports hsa-miR-4330 and MAGE-A8 as Candidate 
Genes 
The internal primer pairs within the micro RNA hsa-miR-4330 generated the expected 
fragments of 104 bp and 208 bp, as showed in Fig. 16. However, none of these products were 
detected using the patient sample even though several nonspecific PCR products were 
detected, suggestive of mispriming due to the absence of the specific target sequence. This 
result, allied to the array data is a strong indication that the hsa-miR-4330 deletion is not an 
artifact. Unfortunately a further attempt to characterize the deletion breakpoints with across-
deletion primers was unsuccessful, since a fragment with the expected size was not detected, 
most likely due to primer non-specificity. Indeed, there is a high density of repetitive 
sequences flanking the predicted deletion breakpoints, which likely explains the difficulty in 
designing specific primers.  
The deletion spanning MAGE-A8 was validated by PCR in the patient sample, as 
presented in Fig. 16. The internal primer pair generated the 352 bp band only in control 
samples. Again, we could not design across–deletion primers due to the highly repetitive 
nature of the flanking regions and to the presence of a gap in the genome assembly.  
 
Both these deletions were patient-
unique, thus appeared with a frequency of 
0.58% in the cohort of Portuguese 
patients surveyed. Furthermore, to 
overcome the breakpoint mapping 
difficulties, we used aCGH platform with 
high resolution for these regions and 
which allowed us to refine the 
breakpoints. 
 
 
As shown by Fig. 17, it was only possible to narrow down the 5’ breakpoint of the deletion 
encompassing hsa-miR-4330, as we avoided placing probes on the 3’ flanking highly 
repetitive regions. Thus, the first probe detected outside the deletion was placed at 
149944904, while the last probe detecting the deletion on the 5’ end was at 150079419 
MAGE-A8 
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Fig. 16 – Internal PCR amplification fragments 
absent in patient sample. C1 – Control sample 1; C2 – 
Control sample 2; PS – Patient sample from stock. 
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(according to NCBI build from Feb. 2009 (GRCh37/hg19)). Additionally, the last probe on the 
3’ end detecting the deletion was located at 150090349. 
 
In the case of MAGE-A8, the first probe detected outside the deletion on the 5’ end is 
located at 148683884, and the last probe detected inside the deletion at 148693939 
(according to NCBI build from Feb. 2009 (GRCh37/hg19)). In turn, on the 3’ end, the last 
probe inside the deletion is at 148835509, while the first probe detected outside is located at 
148939758, depicted on Fig. 18. A gap in the genome assembly at the 3’ end of the deletion 
compromised the precise mapping of the breakpoint, represented in Fig.18. However, as the 
aCGH included a probe after this gap region, it allowed the determination of the deletion 
length, from 106 015 to 141 036 bp, with higher precision.  
hsa-miR-4330 
Fig. 17 - aCGH breakpoint analysis for hsa-miR-4330 deletion. 
MAGE-A8 
Fig. 18 - aCGH breakpoint analysis for MAGE-A8 deletion. 
Assembly Gap 
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11p13 Deletion Validated by MLPA Reveals WT1 Haploinsufficiency 
The 11p13 deletion of about 1 Mb spans several genes - WT1, PRRG4, QSER1, TCP11L1, 
CSTF3 and HIPK3 - as depicted in Fig. 19. Based on the size of the WT1 deletion on 
chromosome 11, encompassing a large number of probes on the Affymetrix SNP there is 
strong indication from array results alone that this region is indeed deleted.  
 
In order to obtain additional confirmation, four SNPs within the 11p13 deletion, targeted 
in the SNP array, were amplified and subsequently sequenced to verify SNP homozygosity 
(due to hemizygosity). As this locus is present on an autosome, amplification of 11p13 
internal fragments was expected both from controls (having 2 copies of the region) and from 
the patient sample (having one remaining copy) and this is corroborated by the results 
presented in Table 6. In fact, the sequencing results show that the patient is homozygous for 
the four SNPs within the sequenced fragments. This supports the presence of a deletion in 
one of the copies of this genomic region in this patient.  
 
Table 6 – Sequencing results of SNPs within 11p13 targeted in the SNP array confirm homozygosity. 
11p13 Internal SNPs 
SNP_A-8625595 
 G/T  (+ strand) 
 Ref. Allele: G 
 MAF: 20% 
 
SNP_A-8291279 
 A/G  (- strand) 
 Ref. Allele: G 
 MAF: 27% 
SNP_A-8528753 
 G/T  (+ strand) 
 Ref. Allele: G 
 MAF: 30% 
SNP_A-2142682 
 T/G  (+ strand) 
 Ref. Allele: G 
 MAF: 34% 
    
 
Fig. 19 - UCSC Genome Browser screen shot showing the 11p13 deletion (in red) encompassing genes 
from WT1 to HIPK3. 
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The following approach was based on MLPA, using a kit targeted for genes related to 
mental syndromes, such as WAGR, which included four probes in our region of interest – 
three probes within the WT1 gene and one in HIPK3. Normalization of the obtained values 
was performed as described in the Methods section. Regarding standard values for 
autosomes, deletions are validated when the normalized ratio between sample and controls 
is below 0.65 and in our experiments only the probes present within our region of interest 
(on WT1 and HIPK3) were bellow this threshold, as depicted by the graph presented in Fig. 
20.  
 
 
As an attempt to precisely map the breakpoints of this 
deletion, across-deletion primers were designed and tested 
with success, resulting in the amplification of a product of 
approximately 12000 bp, visible on Fig. 21.  This was 
possible when using a DMSO concentration of 5%, 
following the ExpandLong Range dNTPack Protocol (see 
Methods). Sanger sequencing of the resultant fragment is 
ongoing, using a primer walking approach (Fig. 22).  
  
 
0,00
1,35
0,65 
Fig. 20 - MLPA results show a normalized ratio below 0,65 for probes on WT1 and HIPK3 (the 
extremities of the 11p13 deletion), confirming hemizygosity of this region. 
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      DMSO 
11p13 Across-del 
12,000 bp 
Fig. 21 - 11p13 across-deletion 
PCR resulted in amplification of a 
12000 bp product. 
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The combined results validate this novel 11p13 deletion. Moreover, this deleted region 
encompasses a gene involved in gonadal development and maintenance, WT1, which suggests 
that the deletion of this gene likely underlies the spermatogenic impairment phenotype 
observed in the patient. 
 
Absence of WT1 coding mutations in the patient 
After confirming the deletion on 11p13 encompassing the gene WT1, the next step was to 
verify if the single WT1 allele present in the patient was intact and did not contain any coding 
mutations. Sanger sequencing of exons 1a to 10 revealed 100% identity between the 
sequence amplified from the patient gene and the reference gene sequence NG_009272 
annotated in NCBI, and thus with absence of mutations. Alignments to the reference sequence 
were performed using Geneious Software [2] and BLAT tool from UCSC. 
Fig. 23 – WT1 reference gene alignments with patient’s exon sequences, revealed no additional 
mutations (Geneious Software [2]) 
Fig. 22 – 11p13 deletion 5’ end flank (about 5 kb) demonstrating the primer walking approach 
and the obtained assembled contigs. Orange – forward primers. Yellow – putative breakpoint. 
(Geneious Software [2]) 
11p13  Deletion 5’ end Flank 
Breakpoint 
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A Novel WT1 Coding Variant Identified in an Azoospermic Patient 
After screening a subgroup of 40 azoospermic patients (including 2 individuals with 
cryptorchidism, 1 with varicocele and 1 with hydrocele), we identified a new coding variant 
c.185C>T (P130L; ENST00000332351) on the first exon of WT1 gene, in one of the patients. 
To confirm this alteration, sequencing was carried out using both the forward and reverse 
primers for this exon, obtaining identical results (Fig. 24).  
 
This is a missense mutation (CCA>CTA) which alters the encoded amino acid from proline 
to leucine, disrupting the proline-rich region. This new variant is present within a critical 
WT1 domain, namely the proline-rich self-association domain. 
PolyPhen-2 tool (http://genetics.bwh.harvard.edu/pph2/) for non-synonymous SNP 
predictions classified this variant as ‘possibly damaging’, as depicted in Fig 25. This tool takes 
into account the phylogenetic conservation of this residue and also the disease-causing 
mutations annotated (described in Methods).   
The HumDiv and HumVar scores were 0.939 and 0.503, respectively. We should consider 
the HumVar as this is the preferred model for the diagnostics of Mendelian diseases, which 
requires distinguishing mutations with drastic effects from all the remaining human 
variation, including abundant mildly deleterious alleles. 
  
1 2 3 4 5 6 7 8 9   10 
Self Association Domain 
Rep Activation Rep 
Zinc Finger Domain 
Fig. 24 - Novel c.185C>T mutation found in WT1 Exon 1, in a patient sample (red line inside box). 
(Red lines –mutations reported to date, showing predominance at the zinc finger domain) On top, the 
sequencing results show the obtained fragments using both the forward and reverse primers, 
confirming the presence of the novel variant. 
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Even though PolyPhen-2 indicates that this alteration may have deleterious effects, in a 
clinical setting it should not be taken as definitely causative. Besides, this variant is probably 
rare, since it appeared once in the cohort of 40 males sequenced, showing a frequency of 
approximately 1.3% in the sample of Portuguese patients surveyed. Genotype data from 
individuals included in the 1000 genomes project, used as controls, revealed no variation at 
this position, suggesting that such variant may be absent from the general population.  
Due to the absence of a crystalographic structure of the WT1 protein, in the Protein 
Database, PolyPhen-2 was not able to predict the effect of this mutation on the structure of 
the protein.  
Fig. 25 - PolyPhen-2 output classifying the c.185C>T variant as “Possibly Damaging”. An orthologue 
alignment to verify conservation at this position is also presented by this tool. 
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Discussion 
Array-based methodologies have been very useful in pursuing the association of copy 
number variation with disease, as previously pointed out. However, caution should be taken 
in the interpretation of results from these experiments due to a non-negligible rate of false 
positives, and candidate CNVs should be validated by other techniques. This is particularly 
true for rare variants that have been observed seldom in the population, or in the case of 
variants being newly reported.  
There are several factors that may influence the performance of individual probes on the 
array [90] and therefore, the greater the number of probes at a given locus, the greater will be 
the confidence level in detecting a CNV in that region. In fact, smaller CNV calls are more 
likely to represent false positives than larger ones. Consequently, it is not surprising that in 
our analysis the CNVs that were not validated (at Xq21.1, Xq25, Xp11.4 and Xq22.1) fall 
within the shorter (<21 kb) putative deletions. As for the putative deletion of about 42 kb in 
Xq26.3, other factors such as the highly repetitive flanking DNA sequences may have 
contributed to a false positive result in the SNP array. The use of hybridization-based assays 
in repeat-rich and duplicated regions has limited power since the analysis assumes each 
location to be diploid in the reference genome, which is not valid in duplicated sequence. 
Given that CNVs show a strong association with segmental duplications in many cases it is 
challenging to determine accurately the location of breakpoints and, thus, copy number 
variation in these regions requires additional validation methods [85]. 
Furthermore, structural variants tend to be located within repetitive DNA, which makes 
their characterization more difficult [85]. Thus, breakpoint characterization by aCGH of our 
deletions counted on high resolution of probes flanking our candidate regions. The placement 
of probes after the gap region on 3’ of the deletion spanning MAGE-A8, gave a more precise 
length of this deletion, from the initial 106 015 bp to 141 036 bp. Besides, it was also possible 
to narrow down the breakpoint areas flanking this deletion. In turn, the deletion spanning 
hsa-miR-4330 was only possible to characterize on the 5’ end and to refine the length of the 
deleteded sequence from the initial 10 381 bp to 10 930 bp. Moreover, the presence of highly 
repetitive flanking regions suggests ectopic recombination between repeats as the likely 
mutation mechanism underlying these deletions. This information will contribute to the 
discovery of the full extent of structural variation in the human genome and understand its 
effects on human disease [85]. 
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In our study, the combination of SNP array with PCR and array CGH or MLPA to validate 
putative structural variants offers a higher confidence in the confirmation of these rare 
variants. Therefore, we were able to validate two patient-specific deletions on the X 
chromosome: MAGE-A8 and hsa-miR-4330. Even though these were unique observations it is 
tempting to address the impact of the absence of these genomic sequences on the phenotype 
under analysis. To provide more insights on their possible role in spermatogenesis pathways, 
bioinformatics tools were used to characterize these rare variants using a functional 
biological pathway approach (described in Material and Methods). 
 
MAGE-A8 (Melanoma-associated antigen 8 or Cancer/testis antigen 1.8) 
The MAGE-A family is part of the MAGE-I subfamily and is composed of 15 similar genes 
clustered at Xq28, including MAGE-A8 (Fig. 26) [56]. Data from UniProt and the CTDatabase 
indicates that MAGE-A8 is thought to play a role in embryonic development and tumor 
transformation or in tumor progression. In fact MAGE-A8 is expressed in tumors of several 
types such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast 
carcinoma, while it is not expressed in normal adult tissues except testis and placenta. 
Furthermore, the microarray expression profile of MAGE-A8 in testis obtained in the 
GermOnline database reveals some evidence of expression in germ cells, particularly in 
spermatocytes [91].  
As testis is the prime adult organ where 
MAGE genes are expressed, it has been 
previously suggested that these genes may 
have a role in spermatogenesis [92]. MAGE-A 
genes have been found to be highly expressed 
in spermatocytes and early spermatocytes 
(such as leptotene, zygotene and diplotene 
spermatocytes), while in pachytene 
spermatocytes and round spermatids they 
showed a diminished expression. Besides, MAGE-A genes are not expressed in elongating 
spermatids and spermatozoa, neither in Sertoli nor in Leydig cells [93,94]. As they have shown 
to be expressed mainly in the initial stages of spermatogenesis, MAGE proteins may be 
intimately related to cell cycle progression, to prepare germ cells for meiosis I and II, and 
early phase of spermiogenesis but not involved in the spermiation process [56]. 
Fig. 26 –The MAGE family. (Doyle 2010 [1]) 
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The biochemical and cellular mechanisms by which MAGE family proteins function in 
tumor, normal, and germ cells have remained elusive, yet, CT-X antigens have been associated 
to cell cycle progression/regulation, transcriptional control, cell survival and apoptosis which 
is supported by the fact MAGE genes appear to be localized more to the nucleus than the 
cytoplasm [56,57]. The MAGE homology domain (MHD), the only region of homology shared by 
all MAGE members is an important site of protein-protein interaction, usually located close to 
the C-terminal [57,95]. Recent studies have shown that several MAGE proteins interact with 
RING domain-containing proteins, through their MAGE homology domain (MHD), and can 
modify and enhance their E3 ubiquitin ligase activity [1,56].  
Many RING domain proteins with E3 ubiquitin ligase activity have been reported to be 
involved in spermatogenesis in mice and humans [96]. Ubiquitination involves orchestrated 
actions of ubiquitin-activating, conjugating and ligating enzymes [97]. RING-domain proteins 
are a large family of E3 ubiquitin ligases, which bind to and localize E2 ubiquitin-conjugating 
enzymes to substrates and facilitate direct ubiquitin transfer from an E2 to the substrate 
[98,99,100]. Many key regulatory proteins are targeted by this machinery early in mitosis and 
meiosis of germ cells. In addition, rapid degradation of cytoplasmic as well as nuclear 
proteins during spermiogenesis also relies on this machinery [25]. 
As an example of RING domain proteins, the Cullin-RING ubiquitin-ligase CRL4 has 
proved to control cell cycle and DNA damage checkpoint response and ensure genomic 
integrity. In fact, inactivation studies of CRL4 by gene-targeting in mice were shown to affect 
male fertility resulting in decreased spermatozoa number, reduced sperm motility and 
defective acrosome formation [25,99]. Thus, enhancement of RING domain proteins activity by 
MAGE genes may perhaps be crucial during male germ cell progression in spermatogenesis.  
MAGE proteins 
Enhance E3 ubiquitin ligase activity 
through association by MHD 
RING-domain E3 
ubiquitin ligases 
MAGE/RING complex regulates: 
 Sperm production 
 Cell cycle progression 
 Quality control/Apoptosis  
(p53 stability) 
 Cell proliferation 
 
Fig. 27 – MAGE-RING complex roles in spermatogenesis. 
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In this study, we have reported the absence of MAGE-A8 from patient DNA. This genomic 
structural variant may be responsible for the severe spermatogenic impairment, by a 
decrease in the modulation of the RING domain proteins essential for proper 
spermatogenesis to occur. Even though MAGE proteins share the MHD domain and thus may 
be involved in similar pathways, MAGE family members show dissimilar 
expression/functions throughout spermatogenensis stages [93]. Therefore, further functional 
studies on this particular MAGE-A8 gene will elucidate not only its specific role in germ cell 
development but also if this gene is a good target for gene therapy. Besides, more patients 
should be screened to verify if this is a recurrent event in azoospermic patients. 
hsa-miR-4330 
Micro RNAs are vital for negative and positive regulation of gene expression and thus are 
likely to be involved in most biological processes, including male germ cell development [7]. In 
fact, expression levels of several miRNAs are particularly high in testis, specifically in 
spermatogonia, pachytene spermatocytes, spermatids, and spermatozoa, when compared 
with somatic cells [101,102]. These observations suggest that miRNAs are likely involved in the 
regulation of gene expression during mitotic, meiotic, and post-meiotic stages of 
spermatogenesis [101]. 
During spermatogenesis, post-transcriptional control of gene expression is highly active 
and is of vital importance due to the fact that germ cells are periodically transcriptionally 
silenced [7,103]. Large-scale gene transcription occurs in two phases: before meiosis (in 
pachytene spermatocytes), and again post-meiotically, and up to two-thirds of these 
transcripts are then stored for translation later in spermatogenesis [7,103]. Increased miRNAs 
levels coincide with both of these waves of active gene transcription [104,105], thus highlighting 
their potential role in the post-transcriptional regulation of genes during spermatogenesis. 
Fig. 28 - The miRNA pathway – mRNA can 
have different fates. High complementarity 
base pairing between the target and miRNA 
combined with the presence of AGO2 causes 
mRNA degradation while mismatched 
pairing between the target and the miRNA 
causes mRNA sequestering in cytoplasmic 
granules or translational repression via a 
number of mechanisms. Under certain 
conditions, miRNA binding has been shown 
to activate translation [7].  
 
 Rare Structural Variants in Severe Spermatogenic Impairment 
 
Catarina Morais Seabra  Page  53 
 
Previously described experiments with disruption of the miRNAs synthesis pathway (Fig. 28) 
have demonstrated that miRNAs are essential for germ cell survival during the colonization 
of the gonads, as dicer null mice reported a dramatic loss of fertility, presenting either Sertoli 
cell only phenotype or germ cell defects [106,107]. Therefore, our results revealing absence of 
hsa-miR-4330 in an azoospermic patient, suggest that this miRNA may be crucial to form 
functional sperm.  
To disclose the physiological function of hsa-miR-4330 in spermatogenesis, its predicted 
target genes with highest mirSVR interaction scores (see Methods) were analyzed through 
information available in bioinformatics databases. According to the miRNA database, the 
targets with highest mirSVR interaction score and with known testis expression were 
C10orf96 (chromosome 10 open reading frame 96), MUM1L1 (melanoma associated antigen 
(mutated) 1-like1) and HMMR (hyaluronan-mediated motility receptor), presented on Table 
7. Interestingly, WT1 gene known for its role in gonadal development and maintenance also 
shows interaction with this miRNA, yet with a lower score.  
Table 7 – hsa-miR-4330 targets with highest scores show noticeable testis expression (results are 
presented in normalized linear scale). WT1 is also regulated by hsa-miR-4330. The dotted red line 
indicates an empirical signal threshold level for background noise [91].  
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Little is known on C10orf96 other than its testis expression profile showing evidence of 
its expression mainly in spermatocytes and, thus, it may have a role in testis function [86]. 
MUM1L1 is a mutated MAGE-1-like1 gene, and thus contains a mutated melanoma-
associated antigen 1 domain. These proteins which contain mutated antigens are expressed 
at high levels on certain types of cancers. Besides, as this protein contains a PWWP domain, it 
is expected to be involved in DNA methylation, DNA repair and regulation of transcription 
(RefSeq, Sep 2011).  
HMMR (or RHAMM) gene encodes a HA receptor that has been linked to regulating cell 
locomotion and density dependent contact inhibition of fibroblasts, smooth muscle cells, 
macrophages, lymphocytes, astrocytes and sperm [108]. In fact, HMMR was localized by 
immunofluorescence along the tail, the midpiece, and the head of sperm. Inhibition of HMMR 
has shown to result in significantly decreased the sperm motility, rendering an important 
role for this glycoprotein in sperm motility [109].  Besides, as it is highly expressed in 
spermatocytes (shown in Table 7), it may be essential the initial steps of meiosis for other 
than motility purposes.  
WT1, a widely studied gene with a well-known function in male gonadal formation and 
maintenance, shows interaction with hsa-mir-4330, suggesting this miRNA has a role in the 
regulation of WT1 gene expression. Studies using an RNAi approach, which mimics the 
principle by which endogenous miRNAs are made, demonstrated that WT1 transcription 
factor requires normal miRNA biogenesis for proper control of germ cell survival and 
spermatogenesis, as WT1 knockdown mice suffered from increased germ cell apoptosis, a 
loss of the adherens junction complex between germ cells and Sertoli cells, and impaired 
fertility [101,110]. 
In summary, there is evidence supporting that hsa-miR-4330 may have a significant role 
in spermatogenesis, by regulating its target genes which in turn show high testis expression 
and have known roles in germ cell formation and maturation. Even though the target genes 
may also be regulated by other miRNAs, this deletion could cause a similar effect as would 
haploinsufficiency, decreasing the regulatory stimuli for those genes. Screening for deletions 
of this miRNA gene in a larger cohort of azoospermic patients will help unveil its association 
with spermatogenesis impairment and thereby its potential as a male infertility biomarker. 
On the other hand, functional studies elucidating hsa-miR-4330 role in spermatogenesis 
pathways should clarify its use as a target for male contraception. In fact, a significant 
advantage of using miRNAs as targets for male contraception is that there would most likely 
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be few side effects, since a number of miRNAs are expressed exclusively in testis but not in 
other tissues [7,101,111,112]. 
 
11p13 Deletion and WT1 Gene 
A non-syndromic patient with a phenotype of severe spermatogenic impairment (non-
obstructive azoospermia) and mild unilateral cryptorchidism presented a novel 11p13 
deletion of approximately 1 Mb, which was detected by the SNP array and then validated by 
MLPA. This result suggests that haploinsufficiency of the genes within this deleted region 
were determinant in the phenotype of this patient. Of particular interest, a copy of the WT1 
gene, a crucial transcription factor for male gonadal formation and differentiation, was also 
deleted.  
Haploinsufficiency of WT1 protein seems to be the likely explanation of the phenotype 
observed in this patient, due to a dosage imbalance of protein production and function. This 
may lead to deficient responses given that the relative levels of WT1 to other protein factors 
are tightly regulated during development. For example the balance of WT1 and DAX1 
determines the transcriptional activation of the AMH gene (responsible for the regression of 
the female Müllerian duct) and a decreased dosage of WT1 protein, albeit functional, will 
dysregulate this process [58,71].  
Besides, mutation screening of WT1 coding sequence in this patient, revealed no 
mutations in the remaining allele. The absence of any of the mutations found in WT1-
assciated syndromes (Denys-Drash or Frasier) further supports the diagnostic of isolated 
spermatogenic impairment in this man [79,81,113,114,115]. 
To date, 11p13 deletions, and thus WT1 gene deletions, have been associated to the 
formation childhood renal cancer, known as Wilms’ Tumor, and/or mental retardation, both 
severe phenotypes. However, this newly described deletion did not encompass the PAX6 
gene, also deleted in WAGR Syndrome, responsible for aniridia which may explain the non-
syndromic phenotype observed in our patient [78]. 
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Novel c.185C>T WT1 Variant 
WT1 mutations reported to date are associated with severe phenotypes, such as 
cryptorchidism, hypospadias, ambiguous genitalia, syndromic complications and renal tumor 
[79,81,113,114]. In fact, the most frequent mutations reported are located within the zinc finger 
region of the WT1 gene. However, the detection of mutations may be biased towards this 
region, as most studies have only focused on the terminal exons of the gene (7 –10), which 
are imperative for DNA-binding and thus, transcriptional regulation.  
Bashamboo, et al. 2010, demonstrated that heterozygous mutations in SF1, involved in 
male sex differentiation along with WT1 (Fig. 9), are associated with severe spermatogenic 
impairment in otherwise healthy men [28]. Motivated by their findings, we sequenced a 
subgroup of azoospermic males and screened for mutations in the WT1 gene, in domains 
other than that involved in DNA binding, which could result in a less severe phenotype, 
namely genital dysfunction. 
In fact, we identified a novel missense c.185C>T variant (P130L; ENST00000332351) in 
exon 1 of WT1 gene from one of the patients, within the self-association domain of the 
protein. This variant modifies an encoded proline to a leucine, which is expected to disrupt 
the unique pattern of the proline-rich region (PRR). Proline is a very unusual amino acid, with 
its side-chain cyclized back on to the backbone amide position. In fact, a sequence of four or 
more proline residues in a row adopts a single preferred conformation in solution, known as 
the polyproline II helix. PRR generally form extended structures and flexible regions that are 
hard to crystallize and, thus, this may be the reason why there is no structure available for 
this region of the WT1 protein [116]. Because of the rapid but non-specific nature of their 
interaction, PRRs are often involved in complex multiple protein association phenomena, as 
those found for the RNA polymerase II pre-initiation complex, the vesicle-associated proteins 
and the SH3 domain binding proteins. The Wilms’ Tumor protein contains a long stretch of 
prolines in a non-repetitive pattern - PLPHFP2SLP2THSPTHP3AP3AP9 – within its 
transcription activation site. Thus, this PRR is likely to be involved in binding [116]. 
Dimerization of WT1 with others proteins, at its N-terminal region, is thought to block the 
repression domain and/or reveal the activation domain, thereby regulating its transcriptional 
activity [117]. Many proteins that interact with the N-terminal of WT1 have been identified, 
such as SF1, CIAO 1, hUBC9, HSP70 and PAX2. Besides, in vitro assays have shown the ability 
of WT1 auto-regulation by homodimerizing through interaction at its first 180 amino acids 
[65,66]. 
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WT1-DDS mutant proteins show a dominant negative effect, by binding normal WT1 
proteins, thus preventing its physiological activity [65]. Similarly, the variant we report may 
disrupt the proline rich N terminal of WT1 protein and lead to a decrease in binding 
specificity of WT1 with its interacting proteins, compromising its regulatory function. 
Furthermore, as SF1 and WT1 are expressed during adulthood in Sertoli cells, this mutation 
may also contribute to poor maintenance of gonadal function [28,72].  
To predict whether the disruption of the proline stretch would be deleterious, we used 
PolyPhen-2 tool. This retrieved a qualitative result classifying the mutation as “possibly 
damaging”. However, for the purpose of genetic counseling it cannot be taken as definitely 
causative, even though there is indication that this variant may have deleterious effects. 
Besides, contrary to the WT1 mutations reported to date which are associated with severe 
diseases of sexual differentiation (DSD), the novel variant described here may have a less 
drastic effect or it may affect a specific function of the protein only crucial at a latter 
developmental stage since this alteration was found in an individual showing isolated 
spermatogenic dysfunction. Also, in this case, a reevaluation of the clinical information on this 
patient will be performed to confirm that no additional abnormalities have been identified 
besides idiopathic NOA. 
Therefore, we provide evidence, yet circumstantial, that alterations in WT1 can be 
associated with severe spermatogenetic impairment in otherwise healthy men. This broadens 
the range of phenotypes associated with mutations in WT1, namely on exon 1. So far, the 
mutations reported on this exon all lead to truncated, hence, dysfunctional WT1 protein 
associated with severe phenotypes such as renal tumor [63,118,77].  
Since this variant was not found in a large sample of control individuals, according to the 
1000 genomes project, this is not a frequent variant in the population. Yet, normospermic 
controls should be screened in order to confirm that this rare allelic variant is patient-
restricted. The analysis of a larger cohort of patients will clarify the recurrence of this event 
in the population or the existence of other mutations in this domain of the protein. 
Additionally, we intend to extend our mutation analysis to the promoter region of the gene, in 
order to verify if any alterations in its regulatory region may be found in these patients. 
Indeed, a mutation decreasing WT1 expression levels could have an impact similar to 
haploinsufficiency caused by deletion.   
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Conclusions 
In this study, we report two rare X-linked structural variants spanning MAGE-A8 and hsa-
miR-4330 in two azoospermic patients, placing these genes amongst the growing list of 
candidate genes for male infertility. Future studies to address the function of MAGE-A8 and 
hsa-miR-4330 and understand their spatial and temporal role in spermatogenesis pathways 
should elucidate the usefulness of these genes as biomarkers of male infertility. Besides, they 
could be used as targets for gene therapy and eventually for male contraception. The 
replication of these findings in other cohorts of patients of European ancestry and using 
fertile individuals as controls will be needed in order to confirm their association with severe 
spermatogenic impairment. If possible, the analysis of patients’ family members will be useful 
to determine whether the deletions have occurred de novo. 
A large 11p13 deletion spanning WT1 gene, crucial for male gonadal development and 
maintenance, was validated in a non-syndromic individual with spermatogenic impairment. 
Haploinsufficiency of WT1 is the most likely cause of azoospermia in this patient, as no other 
germline mutations were detected in the remaining WT1 copy. The characterization of this 
deletion’s breakpoint is ongoing. 
Additionally, we report a novel c.185C>T WT1 missense variant from an azoospermic 
patient. This indicates that WT1 modifications in domains not involved in DNA-binding may 
result in phenotypes of isolated spermatogenic failure, while the mutations reported to date 
were associated with severe forms of gonadal dysgenesis and DSD or with syndromic 
conditions such as WAGR Syndrome, Denys-Drash Syndrome and Frasier Syndrome.  
Finally, our results contribute to the characterization of the genetic architecture of male 
infertility. Further studies will clarify the utility of our candidate genes as biomarkers of male 
infertility. In fact, the implementation of new biomarkers would benefit azoospermic men, 
thereby limiting the need for biopsies, improving diagnosis, patient care and genetic 
counseling.  
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Supplementary Data 
 
Table 8 - Populations targeted by the 1000 Genomes Project. 
E
u
ro
p
e
a
n
 
CEU - Utah residents (CEPH) with Northern and Western European ancestry (CEU) 
FIN-Finnish from Finland 
GBR - British from England and Scotland 
IBS - Iberian populations in Spain 
TSI - Toscani in Italia 
A
fr
ic
a
n
 ASW - African Ancestry in Southwest US 
LWK - Luhya in Webuye, Kenya 
YRI - Yoruba in Ibadan, Nigeria 
A
si
a
n
 CHB - Han Chinese in Beijing, China 
CHS - Han Chinese South 
JPT - Japanese in Toyko, Japan 
A
m
e
ri
c
a
n
 
(a
d
m
ix
e
d
) CLM - Colombian in Medellin, Colombia 
MXL - Mexican Ancestry in Los Angeles, CA 
PUR - Puerto Rican in Puerto Rico 
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Table 9 – Characteristics of the primers designed and used, grouped by their corresponding deletion 
(according to Geneious parameters). 
Primers 
Length 
(bp) 
Tm 
(°C) 
GC 
% 
Product 
Length 
R
P
S
6
K
A
6
 
F2 AGTAGTGCCTCATTCTACACCTTGCT 26 57,57 46,15 
254 bp 
R2 TGCAACAGGGATATGATGCTGCTTGT 26 59,07 56,15 
F3 ACCACAGCCTCCCCTTTCCTGA 22 59,18 59,09 
122 bp 
R3 GGGGTTTTTGTAAGCCGTGGGGA 23 59,31 56,52 
S
TA
G
2
 
F2 TGGGGCTTCCCTGACTGCGA 20 59,82 65,00 
248 bp 
R2 TCCTGAACACTGCCAACCTCAGA 23 57,62 52,17 
F3 GTGACCTTTTCCCATGTTTTGATCCAC 27 57,03 44,44 
247 bp 
R3 GCAAGAGGATGAAGGAGAGTCCGA 24 57,75 54,17 
h
sa
-m
iR
-4
3
3
0
 
F1 CCATGCCATCCCTACCCGGC 20 59,27 70,00 
1.632 bp 
R1 CACCTCCCGTCTCCCCCAGG 20 59,97 75,00 
F2 CACCAGCCAACCTGTCCTGCC 21 59,91 66,67 
104 bp 
R2 CACCTCCCGTCTCCCCCAGG 20 60,04 65,00 
F3 GGCATTGGGCTGGGAACCCC 20 59,97 70,00 
208 bp 
R3 ACTCAGCCCTGCCCCTAGCC 20 59,97 70,00 
TA
F
7
L 
F1 GTGGGTAGTCAAGGAAAACA 20 59,95 45,00 
235 bp 
R1 CCAGTCTTGATGTGTGGAAC 20 60,02 50,00 
F2 TCCTTCTGTCTTTGTGCTTT 20 60,03 40,00 
180 bp 
R2 AAGTTATCGCTTCGATGTGT 20 60,18 40,00 
M
A
G
E
-
A
8
 F2 CTGTCTCCTCTGCTTTCCTT 20 61,24 50,00 
352 bp 
R2 CAGTCCCACCATTTCCTCTA 20 62,38 50,00 
C
X
o
rf
2
7
 
F1 TGGGCTTAAACTGAGCACAAGATGC 25 58,03 48,00 
2.665 bp 
R2 CCAACCTGTCTGGGCTTCCCC 21 59,03 66,67 
Flank5_F ACACATCTGGGCTTAAACTG 20 60,26 45,00 
972 bp 
Flank5_R CTGCCTATTGTATCCCTCTG 20 60,11 50,00 
C
X
o
rf
 -
4
8
 Flank5_F GGAAGGTGTTGACAGAGAAGAC 22 61,67 50,00 
9.329 bp 
Flank5_R GAGAGGACGGAAAGAGTCATAG 22 60,79 50,00 
 Rare Structural Variants in Severe Spermatogenic Impairment 
 
Catarina Morais Seabra  Page  71 
 
 Table 10 - 11p13 and WT1 primers. 
Primers 
Length 
(bp) 
Tm 
(°C) 
GC 
% 
Product 
Length 
1
1
p
1
3
 a
n
d
 W
T1
 
Intern_F2   AGAGAGAACCGAAGACAGC 19 58,66 52,63 
485 bp 
Intern_R2 CCAACCACTCATTCAAGC 18 59,16 50,00 
Intern_F1 CGTGTAGGGGATCGTAAA 18 58,46 50,00 
680 bp 
Intern_R1 CATAGAAGGGCAGGTGAA 18 58,70 50,00 
WT1_Intern_F4 CCTTTGGCATCTTGTCAG 18 59,32 50,00 
214 bp 
WT1_Intern_R4 GCTTCCACGACCTTATTC 18 57,12 50,00 
Exon 1A_F kohler 
[83] 
CAGCGCTGAACGTCTCCA 18 66,72 61,11 
573 bp 
Exon 1A_R kohler 
[83] 
GGGTGTCCTAGAGCGGAGAG 20 65,14 65,00 
WT1_Exons 2+3_F AGCCCCAGACAGATAACA 18 58,08 50,00 
1505 bp 
WT1_Exons 2+3_R TTCCTCCCAGTAAAGACC 18 56,47 50,00 
WT1_Exons 4+5_F CTGGAAAATGTGGAGGCT 18 60,21 50,00 
1386 bp 
WT1_Exons 4+5_R TGCTACCCTGATTACCCA 18 59,00 50,00 
WT1_Exon 6_F GCCTCATCTCATCTGGAAGT 20 60,81 50,00 
1020 bp 
WT1_Exon 6_R GGTGTCCCTGATGTTAAAGG 20 60,78 50,00 
WT1_Exon 7_F CCTCAAGACCTACGTGAATGT 21 60,59 47,62 
458 bp 
WT1_Exon 7_R ACTTTCTCTCTACCACTCTGCTC 23 59,72 47,83 
WT1_Exon 8_F CTAACAAGCTCCAGCGAAGT 20 61,13 50,00 
697 bp 
WT1_Exon 8_R TCATGCCTCACCCTTAGATT 20 61,03 45,00 
WT1_Exon 9_F TAGCAGTGGGCTGATGATAC 20 60,27 50,00 
734 bp 
WT1_Exon 9_R GTAGGGACCTGGCTTATCTCT 21 60,12 52,38 
WT1_Exon 10_F GTTAGCTCAGGGACAGAATGA 21 60,82 47,62 
772 bp 
WT1_Exon 10_R TGACCTCGGGAATGTTAGAC 20 61,49 50,00 
WT1_Across_F3 GTAGGGTGTATGAGAGTTTGCAGGA 25 66,11 48,00 
12 228 bp 
WT1_Across_R3    AGTATGAGATGGACTGAGGCAGGT 24 66,03 50,00 
WT1_Across_Int_F GTACTTGCCCCTTAGAGAGA 20 57,53 50,00 - 
WT1_Across_Int_R AGGGTACAAGGACTAGAGCA 20 57,94 50,00 - 
WT1_Across int_F2 CTGCTCACTCCTGCAATTCT 20 62,15 50,00 - 
WT1_Across int_F3 TGAGGAGTCAGGAGGGAAA 19 62,41 52,63 - 
WT1_Across_Int_F4 TTAACTGGCCAGCACCACAT 20 65,35 50,00 - 
WT1_Across_Int_F5 AGGCCCTGTCTCTCTACTAA 20 57,11 50,00 - 
WT1_Int_Across_F6 GGACTTCCTTATCCTCACTATCTG 24 60,86 45,83 - 
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Table 11 - MLPA Kit P219-B1 PAX6 Normalization Results. 
 
Size Position 
Sample 
Y1979 
Control 
(n=5) 
Sample/Ctrl 
Ratio: 
454 BDNF_Ex11 0,1061 0,0842 1,2601 
206 BDNF_Ex8 0,2132 0,2032 1,0494 
214 FSHB_Ex2 0,1860 0,2116 0,8787 
166 FSHB_Ex3 0,3472 0,3227 1,0758 
142 DCDC1_Ex1 0,1762 0,2189 0,8051 
172 DCDC1_Ex4 0,2472 0,2434 1,0156 
148 ELP4_Ex9 0,2129 0,2255 0,9439 
220 PAX_Ex6 0,2626 0,2429 1,0807 
326 PAX6_Ex10 0,2356 0,2113 1,1150 
427 PAX6_Ex11 0,1802 0,1744 1,0335 
355 PAX6_Ex12 0,1296 0,1369 0,9463 
391 PAX6_Ex14 0,1927 0,1810 1,0646 
301 PAX6_Ex15 0,1180 0,1355 0,8706 
319 PAX6_Ex2A 0,1006 0,0876 1,1481 
409 PAX6_Ex2A 0,0845 0,0750 1,1259 
155 PAX6_Ex3 0,2663 0,3084 0,8634 
383 PAX6_Ex4 0,1073 0,1121 0,9573 
138 PAX6_Ex5 0,2131 0,2234 0,9538 
283 PAX6_Ex8 0,2522 0,2318 1,0880 
240 PAX6_Ex9 0,1858 0,1734 1,0719 
311 DKFZ_up 0,2708 0,2786 0,9721 
418 DKFZ_up 0,1447 0,1493 0,9697 
346 RCN1_Ex1 0,1353 0,1190 1,1371 
226 RCN1_Ex5 0,1498 0,1947 0,7693 
364 LOC646008_down 0,1867 0,1972 0,9470 
445 LOC646008_down 0,1806 0,1897 0,9522 
247 WT1_Ex1 0,1152 0,1913 0,6023 
274 WT1_Ex11 0,0873 0,1453 0,6009 
178 WT1_Ex5 0,0638 0,1380 0,4624 
200 HIPK3_Ex17 0,0499 0,1335 0,3735 
193 LMO2_Ex5 0,1919 0,1870 1,0266 
292 EHF_Ex8 0,1949 0,1712 1,1384 
265 CD44_Ex1 0,1877 0,2018 0,9300 
160 SOX2_Ex1 0,2903 0,2998 0,9685 
256 SOX2_Ex1 0,1924 0,2044 0,9414 
337 SOX2_Ex1 0,1309 0,1998 0,6550 
 
